Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3 by Micah, Angela E et al.
Articles
www.thelancet.com   Vol 396   September 5, 2020 693
Health sector spending and spending on HIV/AIDS, 
tuberculosis, and malaria, and development assistance for 
health: progress towards Sustainable Development Goal 3
Global Burden of Disease Health Financing Collaborator Network*
Summary
Background Sustainable Development Goal (SDG) 3 aims to “ensure healthy lives and promote well-being for all at all 
ages”. While a substantial effort has been made to quantify progress towards SDG3, less research has focused on 
tracking spending towards this goal. We used spending estimates to measure progress in financing the priority areas 
of SDG3, examine the association between outcomes and financing, and identify where resource gains are most 
needed to achieve the SDG3 indicators for which data are available.
Methods We estimated domestic health spending, disaggregated by source (government, out-of-pocket, and prepaid 
private) from 1995 to 2017 for 195 countries and territories. For disease-specific health spending, we estimated 
spending for HIV/AIDS and tuberculosis for 135 low-income and middle-income countries, and malaria in 
106 malaria-endemic countries, from 2000 to 2017. We also estimated development assistance for health (DAH) 
from 1990 to 2019, by source, disbursing development agency, recipient, and health focus area, including DAH for 
pandemic preparedness. Finally, we estimated future health spending for 195 countries and territories from 2018 
until 2030. We report all spending estimates in inflation-adjusted 2019 US$, unless otherwise stated.
Findings Since the development and implementation of the SDGs in 2015, global health spending has increased, 
reaching $7·9 trillion (95% uncertainty interval 7·8–8·0) in 2017 and is expected to increase to $11·0 trillion 
(10·7–11·2) by 2030. In 2017, in low-income and middle-income countries spending on HIV/AIDS was $20·2 billion 
(17·0–25·0) and on tuberculosis it was $10·9 billion (10·3–11·8), and in malaria-endemic countries spending on 
malaria was $5·1 billion (4·9–5·4). Development assistance for health was $40·6 billion in 2019 and HIV/AIDS has 
been the health focus area to receive the highest contribution since 2004. In 2019, $374 million of DAH was provided 
for pandemic preparedness, less than 1% of DAH. Although spending has increased across HIV/AIDS, tuberculosis, 
and malaria since 2015, spending has not increased in all countries, and outcomes in terms of prevalence, incidence, 
and per-capita spending have been mixed. The proportion of health spending from pooled sources is expected to 
increase from 81·6% (81·6–81·7) in 2015 to 83·1% (82·8–83·3) in 2030.
Interpretation Health spending on SDG3 priority areas has increased, but not in all countries, and progress towards 
meeting the SDG3 targets has been mixed and has varied by country and by target. The evidence on the scale-up of 
spending and improvements in health outcomes suggest a nuanced relationship, such that increases in spending do 
not always results in improvements in outcomes. Although countries will probably need more resources to achieve 
SDG3, other constraints in the broader health system such as inefficient allocation of resources across interventions 
and populations, weak governance systems, human resource shortages, and drug shortages, will also need to be 
addressed.
Funding The Bill & Melinda Gates Foundation.
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Introduction
In 2015, the 193 member states of the United Nations (UN) 
adopted the 2030 Agenda for Sustainable Development. 
The agenda identified 17 Sustainable Development Goals 
(SDGs) and 169 targets intended to catalyse “peace and 
prosperity for people and the planet”. Of the 17 goals, 
many address health indirectly (eg, zero hunger [SDG2], 
gender equality [SDG5], and clean water and sanitation 
[SDG6]), while SDG3 focuses directly on health, with the 
objective being to “ensure healthy lives and promote well-
being for all at all ages”.
Substantial effort has been made to quantify the 
progress towards meeting the targets set in SDG3.1,2 
Examples include WHO’s Thirteenth General Programme 
of Work, which provides a framework for tracking 
progress towards the health-related SDGs and research 
done by the Global Burden of Diseases, Injuries, and 
Risk Factors study (GBD) Collaborator Network, while 
less research has focused on tracking spending on SDG 
priority areas, especially how they relate to specific 
SDG3 indicators.3 Tracking financial resources for SDG3 
priority areas is crucial for two distinct reasons. First, 
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any scale-up of the interventions needed to achieve 
the ambi tious health goals will probably require some 
additional resources. As such, tracking how many 
resources are spent on health, when and where those 
resources are spent, and who benefits from them is vital 
for transpar ency and assessment of progress towards the 
goals.4 Furthermore, the amount of financial investment 
in health and how it is spent might be used as a proxy 
for governments’ commitment to achieving SDG3 and 
health services more broadly. Even in instances where 
more resources are not needed to achieve the goals 
(because gains can be made through improvements in 
Research in context
Evidence before this study
The Sustainable Development Goals (SDGs) and their related 
indicators and targets mark a consensus among global leaders 
about the importance of improving and maintaining health 
worldwide. To monitor progress towards the health-related 
SDGs, the United Nation’s Voluntary National Reviews Database, 
WHO, and the Global Burden of Diseases, Injuries, and Risk 
Factors study (GBD) Collaborator Network have measured health 
indicators to monitor achievement of SDG3, and the World Bank 
created the SDG atlas. A multitude of voices are championing 
progress towards achieving the SDGs, with some also proposing 
estimates of the financing needs to meet the related health 
goals. To track financing inputs for health, previous studies by 
the GBD Health Financing Collaborator Network have estimated 
past and projected future total health spending in 195 countries 
and territories from 1995 to 2050, and health investment from 
international donors to low-income and middle-income 
countries between 1990 and 2050. In the most recent study, 
in which spending was estimated in 2018 US$, global health 
spending was found to reach $8·0 trillion (95% uncertainty 
interval 7·8–8·1) comprising 8·6% (8·4–8·7) of the global 
economy in 2016 and was projected to increase to $15·0 trillion 
(14·0–16·0), that is 9·4% (7·6–11·3), of the global economy by 
2050. Additionally, estimates have been published for HIV/AIDS 
spending in low-income and middle-income countries and 
malaria spending in 106 malaria-endemic countries (also from 
the GBD Collaborator Network). Similarly, UNAIDS and WHO 
have estimated for spending on HIV/AIDS, tuberculosis, and 
malaria in many low-income and middle-income countries. 
The studies from the GBD Health Financing Collaborator 
Network showed that in 2016, US$19·9 billion (15·8–26·3) was 
spent on HIV/AIDS and $4·3 billion (4·2–4·4) was spent on 
malaria. The World Malaria Report published by WHO in 2019 
showed that US$2·7 billion was invested in malaria control and 
elimination activities by international partners and governments 
of malaria endemic countries. For HIV/AIDS, UNAIDS Global 
AIDS monitoring report showed that in 2018, $19 billion 
(in 2016 US$) from international and domestic sources was 
spent and the WHO’s Global Report on tuberculosis reported that 
in 2019 $6·8 billion was spent on tuberculosis diagnosis, 
prevention, and treatment services. Additionally, the Sustainable 
Development Solutions Network, the International Monetary 
Fund, World Bank, and Organization for Economic Co-operation 
and Development have offered different methods, assumptions, 
and measures related to the financing needs for SDG3. 
The Working Group on SDG Costing and Financing has worked to 
mobilise costing practices and tools to achieve the SDGs. 
For SDG3 specifically, the Third Edition of the Disease Control 
Priorities in Developing Countries assessed financial needs for 
universal health coverage, while researchers at the Institute of 
Health Metrics and Evaluation have estimated funding gaps to 
achieve universal health coverage. The Department of Health 
Systems Governance and Financing at WHO has also projected 
resource needs to finance transformative health systems towards 
achievement of SDG3. Beyond estimated financing targets, 
needs, and gaps, only four of 27 SDG3 indicators have estimates 
of past or current total spending. These financial estimates are 
not directly comparable due to differences in study designs, 
scopes, and completeness.
Added value of this study
This study is the first to our knowledge, that assesses spending 
on and explores the association with health gains for key SDG3 
targets related to HIV/AIDS (3.3.1), tuberculosis (3.3.2), malaria 
(3.3.3), universal health coverage (3.8.1), financial risk protection 
(3.8.2), and development assistance for health (DAH; 3.b.2). 
We focused on quantifying total health spending on HIV/AIDS, 
malaria, and tuberculosis and DAH contributions. Additionally, 
we provide updated estimates using consistent methods for 
retrospective and prospective total health sector spending. This 
work adds value to existing literature by using similar methods 
as previous studies to quantify progress in financing SDG3 
priority by estimating domestic spending by source spending on 
four SDG3 indicators and DAH funding on eight SDG3 indicators.
Implications of all the available evidence
Tracking progress towards the financing of health systems and 
specific targets associated with SDG3 draws attention to the 
need for sufficient resources to achieve health gains without 
placing financial hardship on households. Monitoring this 
progress requires comparable and consistent estimates in 
financing for health. By providing these estimates, we create a 
foundation for stakeholders to discuss, set, and reach achievable 
financial goals. In particular, for some low-income countries our 
results highlight that the available resources seem insufficient to 
achieve the SDG3 targets by 2030. This study also highlights the 
need to estimate the financing available for the other SDG3 
priority areas. Furthermore, the nuanced evidence on the scale-
up of spending and improvements in health outcomes suggest a 
complex association between spending and health outcomes. 
This complexity highlights that, although more resources are 
probably needed to achieve SDG3, other constraints such as 
inefficient resource allocation, weak governance systems, 
inadequate health workforce, and drug shortages will likely need 
to be addressed to achieve the SDG3 targets.
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efficiency of health systems), knowing precisely how 
much is being spent and for what purpose is essential 
for tracking effectiveness and ensuring an equitable 
distribution of resources. Second, SDG3 target 3.8 
identifies financial risk protection and access to essential 
services as key targets.5 Financial risk protection is 
ensuring that no household endures financial hardship 
due to large spending on health. Achieving SDG3 
target 3.8 not only requries enough resources are available 
to provide the services and interventions needed to 
prevent and treat ill health, but also that an awareness of 
the source of those funds is key. Ensuring that health 
spending does not lead to financial hardship and 
impoverishment, known as catastrophic health spending, 
requires that funds for health be prepaid and pooled 
across individuals via public or private insurance 
schemes.6 The alternative to prepaid and pooled resources 
for health is reliance on out-of-pocket spending, which 
forces households without sufficient resources to choose 
between receiving health care or medical impoverishment.
This study builds on past work and aims to make 
progress towards filling the current gap in knowledge on 
the financing of SDG3 priority areas.7–9 Little evidence 
exists on how much is being spent towards the SDG3 
targets and how this spending relates to changes in 
health outcomes of interest. The objectives of this 
study are to measure spending on SDG3 priority areas 
where estimates are relatively complete and comparable, 
examine the association between outcomes and financ-
ings levels, and identify where resource shortages are 
most apparent for four SDG3 indicators. We quantified 
health spending for universal health coverage; domestic 
and DAH spending on HIV/AIDS, tuberculosis, malaria; 
and DAH spending for reproductive, maternal, new-
born, and child health, tobacco control, non-commu-
nicable diseases, vaccines, and human resources. We 
also evaluated spending against key SDG3 indicators 
for HIV/AIDS, tuberculosis, malaria, universal health 
coverage, and pandemic preparedness. Additionally, 
this research estimates future spending on health up 
to 2030 and 2050 to highlight the expected resource 
availability and, in particular, provides information that 
can be used to identify where more prepaid and pooled 
resources are needed.
Methods
Overview
We measured health sector spending by source; domestic 
spending on HIV/AIDS, tuberculosis, and malaria; and 
development assistance for health (DAH; ie, from donors) 
for as many years as possible with the availability of 
input data. For total health sector spending and domestic 
health spending, we generated estimates for 1995–2017 for 
195 countries and territories; for domestic spending on 
HIV, tuber culosis, and malaria, we generated estimates 
for 2000–17 for 135 low-income and middle-income 
countries (although for malaria, 28 low-income and 
middle-income countries without endemic malaria were 
excluded); and for DAH, we generated estimates for 
1990–2019 and all low-income and middle-income 
countries. Using these health spending estimates, we 
projected health sector spending to 2030 and 2050. 
We define health spending similarly to the System of 
Health Accounts 2011 and the WHO Global Health 
Expenditure Database as spending on basic infrastructure, 
services, and supplies to deliver health care. This health 
spending is exclusive of informal care spending and major 
capital investments, such as building hospitals.
Domestic health spending, 1995–2017
We estimated three sources of domestic health spending: 
government, out-of-pocket, and prepaid private spending.7 
The sum of spending from these three domestic sources, 
plus DAH, equate to total spending on health, meaning 
these four sources are mutually exclusive and collectively 
exhaustive. Government health spending is an aggregate 
of social health insurance and government public health 
programmes. Out-of-pocket health spending captures 
health-care spending by an individual patient or their 
household, excluding insurance premiums paid before 
needing care. Prepaid private-health spending includes 
non-governmental agency spending on health and private 
insurance. To estimate the three domestic health spending 
variables, we extracted data from the WHO Global Health 
Expenditure database for all available countries.10 We 
downloaded the data in current national currency units, 
adjusted for inflation, and then converted to 2019 $US, 
completed our analysis, and then also converted our 
estimates into 2019 purchasing-power parity-adjusted $. 
We used deflator series and exchange rate data based 
on data from the International Monetary Fund World 
Economic Outlook.11 For each extracted datapoint, we used 
the metadata provided by WHO to qualitatively assess the 
quality of data. We assigned a weight to each downloaded 
datapoint on the basis of docu mented source information, 
completeness of metadata, and documented methods of 
estimation (more details are in the appendix [pp 14–21]). 
We then used a spatiotemporal Gaussian process model 
to generate a complete time series of data from 1995 
until 2017 for each country, and 95% uncertainty intervals 
(UIs).12
Domestic spending on HIV/AIDS, tuberculosis, and 
malaria, 2000–17
We generated estimates of domestic spending for three 
communicable diseases included in the SDG target 3.3: 
HIV/AIDS, tuberculosis, and malaria. To generate the 
three disease-specific spending estimates, we used a 
similar overarching strategy as for domestic health 
spending estimates. First, we did a comprehensive 
search and extracted all available and applicable data, 
which we put into a common currency for comparability 
(2019 US$). The input data for our disease-specific 
spending esti mates came from multiple sources.
For System of Health Accounts 
see https://www.who.int/health-
accounts/methodology/en/
For WHO Global Health 
Expenditure Database see 
https://apps.who.int/nha/
database
See Online for appendix
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For HIV/AIDS, we extracted spending data for 135 low-
income and middle-income countries from the National 
AIDS Spending Assessments,13 the Global Fund (including 
concept notes, proposals, and funding landscape docu-
ments), National Health Accounts and subaccounts, 
UNAIDS Global AIDS response progress reports, and 
three online public databases provided by UNAIDS: 
the AIDSinfo database, the HIV financing dashboard, and 
the Asia-Pacific region AIDS Data Hub. Additional details 
on the data sources we used are in the appendix (pp 113–16).
For tuberculosis, we extracted spending data for 135 low-
income and middle-income countries from the WHO 
Global Tuberculosis database, Global Fund (proposals, 
concept notes, and funding landscaping documents), 
National Health Accounts and sub-accounts, WHO Global 
Health Expenditure database,10 National Tuberculosis 
Reports, Ministry of Health Reports, GBD data, and unit 
cost data from WHO-Choosing Interven tions that are Cost 
Effective (CHOICE), and Moses et al.14 Additional details 
on the data sources we used are in the appendix (pp 13–21).
For malaria, we extracted spending data for 106 malaria-
endemic low-income and middle-income countries from 
the World Malaria Report, the Global Fund (including 
concept notes, proposals, and funding landscape docu-
ments), National Health Accounts and sub-accounts, the 
Global Fund Price Quality Reporting, WHO Global Price 
Reporting Mechanism, Management Sciences for Health 
reference prices, Global Affordable Medicine Facility, 
Health Action International database, treatment data 
provided by the Malaria Atlas Project, Demographic and 
Health Surveys, malaria out-of-pocket cost literature, 
malaria inpatient and outpatient cost literature, and 
inpatient and outpatient unit costs from Moses et al.14 
Further details on the data sources we used are in the 
appendix (pp 89–90).
Second, we used a spatiotemporal Gaussian process 
model to generate a complete time series of estimates 
by disease from 2000 to 2017 for each country included. 
For our HIV/AIDS spending estimates, tabulated data 
of annual spending of all components—government, 
out-of-pocket, and prepaid private spending—were 
available, so we used those to generate our estimates. 
For malaria and tuberculosis, little tabulated data 
and estimates on out-of-pocket spending were avail-
able, so we developed out-of-pocket spending estimates 
by taking the product of coverage (ie, volume) and 
unit costs for key services for which users pay out of 
pocket.
Universal health coverage, 2000–17
We extracted the universal health coverage service index 
from the GBD 2017 SDG Collaborators.1 The index 
aggregates across a diverse set of intermediate coverage 
estimates, such as vaccine coverage, and measured of 
health system performance. We extracted data on 
195 countries from 2000 to 2017 used these data in this 
analysis.
No commonly agreed on system exists to differentiate 
between which health spending is intended to help 
countries achieve universal health coverage. Because of 
this, we track pooled health spending as a proxy for 
tracking progress towards financing universal health 
service coverage. Pooled spending is health-care spending 
collected in advance and spread across a large set of 
individuals, and includes government and prepaid private 
spending and DAH.
Estimating DAH, 1990–2019
We defined DAH as the financial and in-kind resources 
transferred through international development agencies 
to low-income and middle-income countries for the 
primary purpose of maintaining and improving health. 
We extracted project disbursement data from online 
databases, annual reports, and financial statements of 
the major inter national development agencies and 
philanthropic insti tutions including the World Bank, 
the Organisation for Economic Co-operation and 
Development’s (OECD’s) Creditor Reporting System, 
and the Bill & Melinda Gates Foundation; details on 
the agencies and institutions included are in the 
appendix (pp 28–33). The estimates of DAH include the 
expenses incurred to administer the grants and loans.
We classified estimates of how DAH funds were 
disbursed into ten mutually exclusive and collectively 
exhaustive health focus areas and 52 programme 
areas on the basis of project descriptions, project 
titles, including pandemic preparedness, and budget 
documents. Disbursement of DAH funds to single 
countries were identified as such, while global initiatives 
and administrative costs were classified separately. 
Administrative costs capture the operational cost of 
running projects—eg, staff salaries. The research and 
development funds that are included in our DAH 
estimates are those that are disbursed through inter-
national development agencies with the primary intent 
of the improvement and maintenance of health in 
low-income and middle-income countries. The DAH 
contributions towards human resources we captured 
here include indirect funding for human resources 
activities, such as per diems, and direct funding for 
human resources for health projects that invest in 
human resources activities, such as training, education, 
and policy development. The health focus areas included 
in this study are HIV/AIDS; tuberculosis; malaria; repro-
ductive, maternal, newborn, and child health; other 
infectious disease; non-communicable diseases; sector-
wide approaches; and health system strengthening. 
Detailed descriptions of the methods we used to isolate 
the disbursements of DAH funds for relevant health 
focus areas and preliminary estimates are in the appendix 
(pp 34–45) and elsewhere.7,15
The estimates presented here of DAH incorporated 
improvements in our methods compared with previous 
years, such as using additional project-level descriptions 
For the Global Fund website see 
http://www.theglobalfund.org/
en
For AIDSinfo database see 
https://aidsinfo.unaids.org/
For UNAIDS HIV financial 
dashboard see 
http://hivfinancial.unaids.org/
hivfinancialdashboards.html
For Asia-Pacific region HIV Data 
Hub see http://aphub.unaids.
org/
For WHO tuberculosis database 
see http://www.who.int/tb/
data/en/
For WHO-CHOICE website see 
https://www.who.int/choice/
cost-effectiveness/en/
For the World Malaria Report 
see https://www.who.int/
malaria/publications/world-
malaria-report-2018/en/
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from the Creditor Reporting System for the allocation of 
disbursements channelled through non-governmental 
organisations and refinement of our keyword search list 
(appendix 34–42).
The Millennium Development Goals (MDGs) were 
eight development goals adopted by the UN in 2000. The 
goals, to be achieved by 2015, included the eradication of 
extreme poverty and hunger; achievement of universal 
primary enrolment; promotion of gender equality and 
empowerment of women; reduction in child mortality, 
HIV/AIDS, malaria, and other diseases; and improvement 
in maternal health. Like the SDGs, the MDGs included 
health specific goals and goals focused on other sectors 
indirectly linked to health. In our analyses, we examine 
spending over the duration of the MDGs, starting in 2000 
up to 2015.
DAH data for 2018 and 2019 are preliminary estimates 
based on budget data and estimation. Detailed infor-
mation on the sources of the budget data and the 
estimation approaches we used are provided in the 
appendix (pp 29–33).
Financial risk protection
We extracted incidence data on catastrophic health 
spending estimates from World Bank World Development 
Indicators database for all years and countries for which 
data were available. Reliance on out-of-pocket spending 
has been shown to be associated with catastrophic health 
spending (also known as medical impoverishment),16,17 
which defined by the World Bank World Development 
index as when a household spends more than 25% of 
annual household income on health.
Health spending in the future: 2018 to 2030 and 2050
We estimated gross domestic product (GDP); general 
government spending (across all sectors); government, out-
of-pocket, and prepaid private health spending; and total 
DAH provided and received from 2018 to 2030 and 2050. 
The methods used for these projections draw heavily from 
our previous research,7,18,19 with the key updates being the 
improvement of the retro spective estimates on which these 
projections are based.
We generated each projection using ensemble modelling 
techniques, such that the estimates are the mean of 
1000 estimated time series from a broad set of models. We 
determined model selection on the basis of out-of-sample 
validation and selection was country and year specific. We 
completed projections sequentially, such that previously 
projected values could be used as covariates and for 
bounding other models. For example, government health 
spending was modelled as a fraction of general govern-
ment spending, which was modelled as a fraction of GDP. 
On the basis of model performance, we modelled GDP as 
a proportion of the population who were of working age, 
which for this study was determined to be aged 20–65 years.
We modelled DAH as a fraction of the donor country’s 
general government spending, or, for private donors, on 
the basis of autoregressive integrated moving average 
(ARIMA) modelling techniques.20 We aggregated total 
DAH across sources. We constructed a separate model 
that projected the fraction of total DAH that each recipient 
was expected to receive. As a country’s own GDP per-
capita increases, the fraction of total DAH received by the 
country is expected to go down. We also modelled when 
countries transi tioned to being high-income and are no 
longer eligible to receive DAH.
All projections incorporated several types of uncertainty. 
We used ensemble modelling techniques to propagate 
model uncertainty.21 We took draws of the variance-
covariance matrix of each estimate’s model to propagate 
parameter uncertainty. We based our projection models 
on the draws of the retrospective estimates to propagate 
data uncertainty. Finally, we added a random walk residual 
to each country's and draw’s projection to propagate 
fundamental uncertainty—ie, to mimic the inherent ran-
domness of the observed data. We generated 95% uncer-
tainty intervals (UIs) by taking the 2·5th and 97·5th 
percentile of the 1000 estimated random draws.
More details are in the appendix (pp 121–41).
Statistical analysis
We report all spending estimates in inflation-adjusted 
2019 US$, although some data are also presented in 2019 
purchasing-power parity-adjusted $ and proportion of 
GDP. We report spending estimates for Venezuela 
in 2014 US$ because necessary exchange rates for 
more recent years were not reliable. We evaluated health 
spending against key indicators relative to SDG3. 
In particular, we extracted estimates of incidence of 
HIV/AIDS, tuberculosis, and malaria from GBD 2017,22 
and the universal health coverage service coverage 
index.1,23
We used different measures to report findings from our 
spending and outcomes analyses. For HIV/AIDS, we 
report spending per prevalent case, because a lot of 
HIV/AIDS spending is determined by the number of 
people undergoing treatment. For malaria, we report 
spending per capita, because as countries move towards 
elimination a lot of malaria spending is on surveillance. 
For tuberculosis, we report spending per incident case, 
because a lot of tuberculosis spending is determined by 
detection of incident cases. Population estimates, both 
retrospective and prospective were also extracted from the 
GBD 2017 study.24 We analysed the association between 
universal health coverage service index and pooled health 
spending by calculating the annualised rate of change in 
each metric from 2000 up to 2017. For our financial risk 
protection analysis, we used the estimates of catastrophic 
health spending and report catastrophic health spending 
estimates from the World Bank World Development 
Indicators database. We divided the extracted estimates 
by total domestic spending on health and then regressed 
on national income using loess regression methods. 
Annualised rate of change is only calculated for countries 
For more on the Millennium 
Development Goals see 
https://www.undp.org/content/
undp/en/home/sdgoverview/
mdg_goals.html
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with more than 1 year of catastrophic health spending 
estimates and when catastrophic health spending was 
greater than zero.25,26 We report estimates of DAH from 
1990 up to 2019 for low-income and middle-income 
countries. The data for 2018 and 2019 are preliminary 
estimates based on budget data and estimation. We 
compared DAH contributions over two periods: 2000 up 
to 2015 and 2015 up to 2019. We also analysed DAH by 
SDG target Spending estimate Existing unofficial financing target
Target 3.1: by 2030, reduce the global maternal mortality ratio <70 per 100 000 livebirths
3.1.1: maternal mortality ratio Reduce to <70 deaths per 
100 000 livebirths by 2030
DAH funding on maternal health was 
$1·5 billion for 135 low-income and 
middle-income countries in 2019
$10·5 billion per year in 120 low-income and 
middle-income countries (UNFPA Nairobi 
Summit ICPD25,27 estimated $115·5 in 
2020–30); $3·3 billion* (2014 US$) per year in 
67 low-income and middle-income 
countries28
3.1.2: skilled birth attendance Universal access (100%) ·· ··
Target 3.2: by 2030, end preventable deaths of newborn babies and children younger than 5 years, with all countries aiming to reduce neonatal 
mortality to at least as low as 12 per 1000 livebirths and under-5 mortality to at least as low as 25 per 1000 livebirths
3.2.1: under-5 mortality Reduce to ≤25 deaths per 
1000 livebirths by 2030
DAH on child health was $8·5 billion for 
135 low-income and middle-income 
countries in 2019
··
3.2.2: neonatal mortality Reduce to ≤12 deaths per 
1000 livebirths by 2030
DAH on child health was $8·5 billion for 
135 low-income and middle-income 
countries in 2019
··
Target 3.3: by 2030, end the epidemics of AIDS, tuberculosis, malaria, and neglected tropical diseases and combat hepatitis, water-borne diseases, and 
other communicable diseases
3.3.1: HIV incidence Eliminate by 2030 Domestic spending in 2017 was 
$10·6 billion and DAH was $9·5 billion in 
2019 for 135 low-income and middle-
income countries
$26·2 billion per year by 2020 and 
$22·3 billion per year by 2030 in 
116 low-income and middle-income 
countries;29 $6·8 billion* per year in 
67 low-income and middle-income 
countries28
3.3.2: tuberculosis incidence Eliminate by 2030 Domestic spending was $9·2 billion in 
2017 and DAH was $1·7 billion in 2019 for 
135 low-income and middle-income 
countries
$13 billion by 2022 in 119 low-income and 
middle-income countries;30 $3·8 billion* per 
year in 67 low-income and middle-income 
countries28
3.3.3: malaria incidence Eliminate by 2030 Domestic spending in 2017 was 
$2·6 billion and DAH was $1·1 billion in 
2019 on malaria for 106 malaria-endemic 
countries
$6·6 billion per year by 202031
3.3.4: hepatitis B incidence Undefined ·· $6 billion* per year in 67 low-income and 
middle-income countries28,32
3.3.5: neglected tropical diseases 
prevalence
Eliminate by 2030 ·· $2·1 billion per year in low-income and 
middle-income countries33
Target 3.4: by 2030, reduce premature mortality from non-communicable diseases by a third through prevention and treatment and promotion of 
mental health and wellbeing
3.4.2: non-communicable disease 
mortality
Reduce by a third by 2030 DAH on non-communicable disease was 
$0·7 billion for 135 low-income and 
middle-income countries in 2019
$28 billion* per year in 67 low-income and 
middle-income countries28
3.4.2: suicide mortality Reduce by a third by 2030 ·· ··
Target 3.5: strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol
3.5.1: substance abuse coverage Undefined ·· $2 billion* per year in 67 low-income and 
middle-income countries28
3.5.2: alcohol use Undefined ·· ··
Target 3.6: by 2020, halve the number of global deaths and injuries from road traffic accidents
3.6.1: road injury mortality Reduce by half by 2020 ·· ··
Target 3.7: by 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, 
and the integration of reproductive health into national strategies and programmes
3.7.2: family planning need met, 
modern contraception methods
Universal access (100%) DAH on family planning was $1·2 billion 
for 135 low-income and middle-income 
countries in 2019
$6·2 billion per year in 120 low-income and 
middle-income countries (UNFPA Nairobi 
Summit ICPD25, estimated $68·5 billion 
for 2020–30)34
3.7.2: adolescent birth rate Undefined ·· ··
(Table 1 continues on next page)
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health focus area specifically reporting contributions 
towards reproductive, maternal, newborn and child 
health, tobacco control, vaccines, non-commu nicable 
diseases, and human resources. Finally, we report global, 
income group, region, and country-specific estimates. 
Income groups are based on World Bank income group 
classification from 2019, while regions are GBD super-
regions (central Europe, eastern Europe, and central Asia; 
SDG target Spending estimate Existing unofficial financing target
(Continued from previous page)
Target 3.8: achieve universal health coverage, including financial risk protection, access to quality essential health-care services, and access to safe, 
effective, quality, and affordable essential medicines and vaccines for all
3.8.1: universal health coverage 
service coverage index
Universal access (100%) Domestic spending in 2017 and donor 
funding in 2019 on health was $7·9 trillion 
(95% UI 7·8–8·0) and $40·6 billion for 
195 countries
$274–371 billion* per year in 67 low-income 
and middle-income countries;28 
$575·57 billion† in 188 countries;14 
$113–223 billion† in 83 low-income and 
lower-middle income countries;14,35 $76 per 
captia per year in 34 low-income countries 
and $110 per capita per year in 49 lower-
middle income countries;36 $110‡ per capita 
per year in 32 low-income developing 
countries; and $175‡ per captia in 27 other 
low-income developing countries (required 
budget outlays)37
3.8.2: financial risk protection <10% or <25% of total 
expenditure or income
·· ··
Target 3.9: by 2030, substantially reduce the number of deaths and illnesses from hazardous chemicals and air, water, and soil pollution and 
contamination
3.9.1: air pollution mortality Undefined ·· $8·1 billion* per year in 67 low-income and 
middle-income countries28
3.9.2: WaSH mortality, Undefined ·· ··
3.9.3: poisoning mortality Undefined ·· ··
Target 3.a: strengthen the implementation of the WHO Framework Convention on Tobacco Control in all countries, as appropriate
3.a.1: smoking prevalence Undefined DAH on tobacco control was $0·1 billion 
for 135 low-income and middle-income 
countries in 2019
Target 3.b: support the research and development of vaccines and medicines for communicable and non-communicable diseases that primarily affect 
developing countries; provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement 
and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on TRIPS regarding flexibilities to 
protect public health, and, in particular, provide access to medicines for all
3.b.1: vaccine coverage Coverage of all target 
populations (100%)
DAH on immunisation was $3·1 billion for 
135 low-income and middle-income 
countries in 2019
$1·4 billion* per year in 67 low-income and 
middle-income countries28
3.b.2: developmental assistance 
for research and health
Undefined DAH on health was $40·6 billion for 
135 low-income and middle-income 
countries in 2019
··
3.b.3: essential medicines Coverage of all target 
populations (100%)
DAH on immunisation was $3·1 billion for 
low-income and middle-income countries 
in 2019
$1·4 billion* per year in 67 low-income and 
middle-income countries28
Target 3.c: substantially increase health financing and the recruitment, development, training, and retention of the health workforce in developing 
countries, especially in the least developed countries and small island developing states
3.c.1: health worker density Undefined DAH on human resources was $4·0 billion 
for 135 low-income and middle-income 
countries in 2019
$8·1 billion* per year in 67 low-income and 
middle-income countries28
Target 3.d: strengthen the capacity of all countries, particularly developing countries, for early warning, risk reduction, and management of national 
and global health risks
3.d.1: international health 
regulation capacity
Undefined DAH on human resources was $4·0 billion 
for 135 low-income and middle-income 
countries in 2019
$8·1 billion* per year in 67 low-income and 
middle-income countries28
Spending data are reported in inflation adjusted 2019 US$, unless otherwise indicated. Data for HIV/AIDS and tuberculosis are reported for 135 low-income and middle-
income countries, for malaria are for 106 malaria-endemic countries, for universal health coverage for 195 countries and territories, and for DAH for each SDG3 indicator for 
135 low-income and middle-income countries except malaria. Existing unofficial financing targets have been extracted from literature review. Low-income and middle-income 
countries are grouped as defined by 2019 World Bank classification. SDG=Sustainable Development Goal. DAH=development assistance for health. UNFPA=United Nations 
Population Fund. ICPD25=25th International Conference on Development. WaSH=water, sanitation, and hygiene. TRIPS=Trade-Related Aspects of Intellectual Property Rights. 
*2014 US$. †2017 US$. ‡2018 US$.
Table 1: Health-related goals, health indicators, health targets, and related spending for SDG3 targets
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high-income; Latin America and Caribbean; north Africa 
and the Middle East; south Asia; southeast Asia, east 
Asia, and Oceania; and sub-Saharan Africa). Argentina is 
the only country in the World Bank category of low-
income and middle-income countries to fall in the GBD 
high-income super-region; hence, in the present study 
we do not include Argentina, and its GBD super-region, 
in figures that disaggregate by GBD super-region. We 
report aggregate rates that reflect the group of countries 
or region as a whole, rather than a mean across the 
countries in that group or region.
We did all analyses using R (version 3.6.0) and Stata 
(version 15). All spending estimates used in this analysis 
are publicly available on the Global Health Data Exchange 
website.
Role of the funding source
The funder of this study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study, and AEM and JLD had final responsibility for the 
decision to submit for publication.
Results
Table 1 lists the SDG3 targets and the associated 
indicators for monitoring these targets, and reports 
existing estimates of financing needed for attaining these 
targets and our spending estimates. The targets and 
indicators were determined and agreed on by the 
member states of the UN, while the financing targets are 
unofficial estimates of resources needed produced by 
other researchers. Our estimates of disease-specific 
spending focus on domestic and DAH spending among 
135 low-income and middle-income countries while 
spending on universal health coverage is measured for 
195 countries and territories including high-income 
countries.
Globally, total health spending has increased since 
the start of the SDGs in 2015, reaching $7·9 trillion 
(95% UI 7·8–8·0) in 2017, and is expected to increase to 
$11·0 trillion (10·7–11·2) by 2030, and $16·7 trillion 
(16·0–17·4) in 2050, although with substantial disparity 
across countries. In 2017, in low-income and middle-
income countries, $20·2 billion (17·0–25·0) was spent 
on HIV/AIDS, $10·9 billion (10·3–11·8) was spent on 
tuberculosis, and in 106 malaria-endemic countries, 
$5·1 billion (4·9–5·4) was spent on malaria. DAH was 
estimated to be $40·6 billion in 2019, the most recent 
year for which data are available. Estimates of DAH in 
2019were also available for the following SDG3 health 
areas: maternal health ($1·5 billion), neonatal and child 
health ($8·5 billion), HIV/AIDS ($9·5 billion), tuber-
culosis ($1·7 billion), malaria ($2·3 billion), non-commu-
nicable diseases ($735·0 mil lion), family planning 
($1·2 billion), tobacco control ($66·2 million), vaccine 
($3·1 billion), and human resources ($4·0 billion). 
Spending for several SDG3 indicators, including 
hepatitis B incidence (3.3.4), substance abuse (3.5.1–5.2), 
road injuries (3.6.1), adoles cent birth rate (3.7.2), and 
chemical and environmental pollution (3.9.1–9.3) do 
not have a large, comparable set of spending estimates 
for either development assistance or domestic spending 
and so are not included in these analyses.
In 2019, DAH for pandemic preparedness was 
estimated to be $374 million (<1% of total DAH). 
$2·4 billion (6%) of all DAH was for infectious diseases 
(other than HIV/AIDS, tuberculosis, and malaria) 
in 2019, but these funds were generally spent on treat-
ment or disease focused efforts rather than pandemic 
preparedness more broadly. Despite DAH for pandemic 
preparedness being such a small fraction of total DAH, 
DAH for pandemic preparedness has grown faster 
than total DAH over the past 10 years. Since 2010, DAH 
for pandemic preparedness has more than doubled 
(increasing 8·1% annually from $185·8 million in 
2010), while total DAH has increased by only 1·9% 
annually. The develop ment agency that provided the 
most DAH for pandemic preparedness in 2019 was 
the WHO.
In 2017, global health spending per capita was $1048 
(95% UI 1034–1062). Of this amount, 81·3% (80·7–81·8) 
was financed by domestic government and prepaid 
private health spending (table 2). Most health spending 
was in high-income countries, where health spending 
was $5307 (5262–5351) per capita in 2017, of which 
86·0% (85·7–86·2) was government and prepaid private 
health spending. In 2017, spending in upper-middle-
income countries was $487 (457–520) per capita and 
in lower-middle-income countries was $84 (76–93) per 
capita. Of $37 (36–39) spent per capita in low-income 
countries in 2017, 30·9% (28·5–33·6) was government 
and prepaid health spending.
Total HIV/AIDS spending disaggregated by financing 
source in 135 low-income and middle-income countries 
for 2000–17 is shown in figure 1A. For these countries, 
which included 93·9% (95% UI 91·2–96·3) of the glo-
bal HIV incidence and 98·3% (98·2–98·4) of global 
HIV/AIDS deaths in 2017, total spending on HIV/AIDS 
was $4·3 billion (3·2–5·9) in 2000 and increased to 
$20·2 billion (17·0–25·0) in 2017, increasing at an 
annualised rate of 9·62% (8·86–10·35) between 2000 
and 2017.23,38 Between 2000 and 2010, DAH for 
HIV/AIDS increased the fastest of all financing sources, 
growing at an annualised rate of 22·12%, although this 
annualised growth rate decreased to –1·64% between 
2010 and 2017. In 2017, DAH for HIV/AIDS was 
$9·6 billion, with 49·4% being spent on grant admin-
istrations and global initiatives. In 2017, government 
spending on HIV/AIDS reached $9·7 billion (6·9–13·3), 
having increased at an annualised rate of 8·86% 
(8·40–9·34) since 2000. The amount sourced by out-of-
pocket spending did not substantially increase, being 
$478·5 million (165·6–1069·9) in 2000 and $589·4 million 
(214·9–1347·9) in 2017. Total HIV/AIDS spending from 
For Financial Global Health 
data on the Global Health Data 
Exchange website see 
http://ghdx.healthdata.org/
series/financing-global-health-
fgh
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Health spending per capita, 2019 US$ Health spending per capita, 2019 
purchasing-power parity-adjusted $
Total health spending per GDP, % Total government health spending and 
prepaid private spending per total 
health spending, %
2017 2030 2017 2030 2017 2030 2017 2030
Global 1048 
(1034–1062)
1285 
(1257–1316)
1418 
(1393–1445)
1816 
(1766–1871)
9·7% 
(9·6–9·8)
10·5% 
(10·1–10·9)
81·3% 
(80·7–81·8)
82·9% 
(82·1–83·6)
World Bank income groups
High-income 5307 
(5262–5351)
6596 
(6482–6708)
5825 
(5777–5872)
7265 
(7147–7385)
12·2% 
(12·1–12·3)
14·0% 
(13·5–14·4)
86·0% 
(85·7–86·2)
87·8% 
(87·5–88·1)
Upper-middle-
income
487 
(457–520)
808 
(740–885)
1053 
(995–1118)
1701 
(1571–1852)
5·7% 
(5·3–6·1)
6·8% 
(6·0–7·6)
66·9% 
(64·2–69·6)
73·0% 
(69·6–76·1)
Lower-middle-
income
84 
(76–93)
127 
(114–141)
289 
(261–322)
439 
(391–496)
3·9% 
(3·5–4·3)
4·1% 
(3·6–4·6)
41·6% 
(36·9–46·1)
45·7% 
(40·1–51·0)
Low-income 37 
(36–39)
45 
(42–48)
119 
(113–126)
141 
(132–152)
5·3% 
(5·0–5·7)
4·8% 
(4·4–5·3)
30·9% 
(28·5–33·6)
36·9% 
(33·6–40·4)
Central Europe, 
eastern Europe, 
and central Asia
538 
(518–560)
700 
(672–730)
1332 
(1276–1390)
1726 
(1656–1806)
5·9% 
(5·7–6·2)
6·4% 
(6·0–6·8)
65·9% 
(64·1–67·7)
68·6% 
(66·8–70·5)
Central Asia
Armenia 403 
(364–447)
538 
(483–597)
966 
(872–1070)
1287 
(1156–1428)
9·7% 
(8·5–10·9)
9·7% 
(8·3–11·2)
16·0% 
(12·8–19·6)
17·7% 
(13·9–21·8)
Azerbaijan 304 
(267–343)
368 
(321–418)
1268 
(1115–1433)
1535 
(1339–1747)
6·6% 
(5·8–7·4)
6·7% 
(5·6–8·0)
17·4% 
(13·6–22·0)
18·3% 
(13·5–23·8)
Georgia 307 
(267–354)
521 
(449–606)
870 
(757–1003)
1477 
(1274–1718)
8·0% 
(6·9–9·3)
10·3% 
(8·2–12·9)
41·4% 
(34·5–48·5)
55·8% 
(48·6–63·0)
Kazakhstan 292 
(249–340)
344 
(286–411)
949 
(811–1105)
1118 
(930–1339)
3·4% 
(2·9–3·9)
3·1% 
(2·5–3·9)
67·0% 
(60·2–73·1)
63·8% 
(55·2–71·5)
Kyrgyzstan 82 
(68–99)
99 
(80–121)
256 
(210–309)
307 
(250–376)
6·6% 
(5·4–7·9)
7·1% 
(5·6–9·0)
38·9% 
(30·8–48·1)
44·3% 
(34·0–55·1)
Mongolia 162 
(139–188)
226 
(191–267)
563 
(484–653)
786 
(664–929)
4·2% 
(3·6–4·9)
4·4% 
(3·6–5·4)
57·1% 
(50·0–63·9)
61·1% 
(53·6–68·0)
Tajikistan 59 
(48–74)
68 
(54–86)
247 
(200–305)
284 
(224–358)
7·3% 
(5·9–9·0)
7·1% 
(5·4–9·3)
28·5% 
(20·5–37·3)
29·0% 
(20·3–39·5)
Turkmenistan 585 
(523–656)
768 
(683–859)
1417 
(1265–1588)
1858 
(1654–2079)
8·1% 
(7·3–9·1)
7·7% 
(6·6–9·1)
26·7% 
(21·8–32·3)
25·5% 
(19·8–32·0)
Uzbekistan 88 
(72–106)
124 
(101–151)
479 
(390–577)
676 
(548–823)
5·8% 
(4·4–7·4)
6·3% 
(4·4–8·6)
46·0% 
(36·6–56·0)
50·4% 
(40·4–60·1)
Central Europe
Albania 364 
(312–428)
607 
(516–725)
933 
(799–1096)
1554 
(1321–1856)
7·3% 
(6·3–8·7)
9·7% 
(7·8–12·0)
67·4% 
(57·5–75·4)
74·5% 
(66·5–81·2)
Bosnia and 
Herzegovina
531 
(474–590)
838 
(741–953)
1325 
(1182–1471)
2090 
(1848–2378)
9·7% 
(8·6–10·9)
11·9% 
(10·1–13·8)
71·2% 
(66·5–76·0)
76·9% 
(72·2–80·8)
Bulgaria 713 
(657–774)
1161 
(1052–1280)
1853 
(1707–2012)
3018 
(2733–3327)
8·1% 
(7·5–8·8)
9·6% 
(8·1–11·1)
52·8% 
(48·8–57·2)
59·9% 
(55·5–64·2)
Croatia 900 
(824–980)
1165 
(1011–1330)
1680 
(1539–1831)
2175 
(1889–2484)
6·5% 
(5·9–7·1)
7·1% 
(6·0–8·3)
89·1% 
(86·5–91·3)
89·9% 
(87·4–92·0)
Czech 
Republic
1585 
(1515–1665)
2308 
(2120–2529)
2694 
(2575–2829)
3922 
(3602–4298)
7·2% 
(6·6–7·9)
8·4% 
(6·9–10·5)
85·2% 
(83·5–86·7)
87·1% 
(85·3–88·7)
Hungary 1107 
(1042–1180)
1445 
(1343–1559)
2157 
(2030–2299)
2816 
(2617–3039)
7·0% 
(6·5–7·4)
7·2% 
(6·5–8·0)
73·0% 
(70·6–75·3)
74·1% 
(71·4–76·7)
Montenegro 672 
(518–870)
877 
(674–1143)
1555 
(1198–2012)
2029 
(1559–2645)
8·4% 
(6·4–10·8)
8·7% 
(6·5–11·4)
72·0% 
(62·2–81·1)
73·6% 
(62·8–82·7)
North 
Macedonia
433 
(342–550)
600 
(466–759)
1170 
(925–1487)
1623 
(1259–2051)
7·6% 
(6·0–9·7)
8·8% 
(6·7–11·1)
67·9% 
(57·7–77·1)
71·7% 
(62·0–80·3)
Poland 882 
(827–945)
1381 
(1274–1498)
2003 
(1879–2145)
3135 
(2894–3402)
6·5% 
(6·1–6·9)
7·5% 
(6·6–8·6)
77·1% 
(74·4–79·6)
80·1% 
(77·5–82·5)
Romania 585 
(535–641)
955 
(819–1104)
1320 
(1207–1446)
2155 
(1849–2492)
5·1% 
(4·7–5·6)
5·9% 
(4·8–7·1)
79·0% 
(74·9–82·4)
81·9% 
(77·6–85·6)
Serbia 465 
(423–512)
666 
(596–743)
1163 
(1059–1281)
1666 
(1492–1858)
7·0% 
(6·3–8·0)
7·3% 
(6·1–8·7)
58·2% 
(53·8–62·9)
59·7% 
(54·6–64·4)
(Table 2 continues on next page)
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Health spending per capita, 2019 US$ Health spending per capita, 2019 
purchasing-power parity-adjusted $
Total health spending per GDP, % Total government health spending and 
prepaid private spending per total 
health spending, %
2017 2030 2017 2030 2017 2030 2017 2030
(Continued from previous page)
Slovakia 1249 
(1184–1315)
1640 
(1489–1798)
2336 
(2214–2459)
3067 
(2785–3364)
6·8% 
(6·5–7·2)
7·1% 
(6·1–8·2)
81·7% 
(79·5–83·8)
82·6% 
(79·9–85·2)
Slovenia 2014 
(1913–2120)
2621 
(2471–2777)
2974 
(2825–3130)
3870 
(3649–4101)
8·3% 
(7·8–8·7)
9·2% 
(8·5–10·2)
87·8% 
(86·5–89·0)
88·9% 
(87·6–90·0)
Eastern Europe
Belarus 373 
(330–422)
470 
(387–576)
1173 
(1038–1327)
1478 
(1215–1813)
5·9% 
(5·2–6·7)
6·3% 
(5·0–7·9)
70·3% 
(64·5–75·4)
72·1% 
(64·8–78·8)
Estonia 1400 
(1338–1462)
1812 
(1662–1970)
2164 
(2069–2261)
2802 
(2569–3045)
6·4% 
(6·1–6·7)
7·0% 
(6·2–7·9)
76·7% 
(74·8–78·5)
78·5% 
(76·2–80·7)
Latvia 1005 
(953–1061)
1278 
(1186–1377)
1741 
(1651–1839)
2213 
(2054–2386)
6·0% 
(5·7–6·4)
6·3% 
(5·6–7·1)
57·7% 
(54·9–60·3)
59·1% 
(55·5–62·4)
Lithuania 1139 
(1081–1201)
1595 
(1477–1713)
2171 
(2062–2289)
3041 
(2816–3267)
6·5% 
(6·1–6·8)
7·4% 
(6·4–8·5)
67·8% 
(65·3–70·1)
71·5% 
(68·6–73·9)
Moldova 215 
(184–250)
288 
(245–340)
500 
(428–583)
671 
(570–792)
7·9% 
(5·9–11·1)
8·9% 
(5·8–14·6)
51·8% 
(44·6–59·5)
56·7% 
(48·1–64·6)
Russia 574 
(526–630)
681 
(612–756)
1537 
(1409–1688)
1825 
(1639–2025)
5·3% 
(4·8–5·8)
5·4% 
(4·7–6·3)
59·9% 
(55·3–64·3)
61·1% 
(56·4–66·3)
Ukraine 219 
(187–255)
248 
(212–294)
618 
(527–719)
701 
(599–828)
6·8% 
(5·8–8·0)
7·0% 
(5·7–8·7)
46·1% 
(39·2–53·7)
48·1% 
(40·7–56·6)
High-income 5760 
(5707–5808)
7106 
(6973–7229)
6175 
(6121–6225)
7597 
(7460–7725)
12·6% 
(12·5–12·8)
14·5% 
(14·0–15·0)
86·2% 
(86·0–86·5)
88·0% 
(87·7–88·3)
Australasia
Australia 5195 
(5108–5280)
6003 
(5868–6154)
5181 
(5095–5266)
5987 
(5852–6137)
9·9% 
(9·3–10·8)
10·6% 
(9·5–12·0)
81·8% 
(81·1–82·5)
83·3% 
(82·5–84·1)
New Zealand 4068 
(3970–4174)
4755 
(4562–4936)
4066 
(3969–4172)
4754 
(4560–4934)
9·9% 
(9·6–10·3)
11·1% 
(10·2–11·9)
86·4% 
(85·4–87·2)
87·7% 
(86·7–88·6)
High-income Asia Pacific
Brunei 690 
(634–750)
766 
(637–902)
1919 
(1764–2085)
2130 
(1773–2509)
2·4% 
(2·2–2·6)
2·6% 
(2·1–3·2)
94·7% 
(93·3–95·8)
95·2% 
(93·6–96·4)
Japan 4290 
(4148–4438)
5321 
(5037–5597)
4784 
(4626–4950)
5934 
(5617–6242)
10·7% 
(10·4–11·1)
12·0% 
(11·0–12·9)
87·1% 
(86·3–87·9)
88·6% 
(87·6–89·5)
Singapore 2739 
(2624–2873)
3698 
(3314–4168)
4393 
(4208–4608)
5931 
(5314–6685)
4·5% 
(4·2–4·8)
5·6% 
(4·8–6·5)
67·7% 
(65·9–69·5)
73·7% 
(70·4–77·0)
South Korea 2118 
(2041–2205)
3384 
(3118–3613)
2993 
(2885–3116)
4782 
(4406–5107)
7·2% 
(6·8–7·6)
10·2% 
(8·8–11·7)
66·5% 
(65·0–68·0)
74·6% 
(72·1–76·8)
High-income North America
Canada 4919 
(4840–5003)
5601 
(5451–5762)
5410 
(5323–5501)
6159 
(5994–6337)
10·7% 
(10·6–10·9)
12·1% 
(11·4–12·8)
85·8% 
(85·1–86·4)
87·3% 
(86·6–87·9)
Greenland 6559 
(6196–6981)
8140 
(7578–8745)
4880 
(4610–5195)
6057 
(5638–6507)
11·8% 
(10·7–13·2)
13·1% 
(10·7–16·1)
100·0% 
(100·0–100·0)
100·0% 
(100·0–100·0)
USA 10 243 
(10 087–10 390)
12 734 
(12 337–13 115)
10 243 
(10 087–10 390)
12 734 
(12 337–13 115)
16·4% 
(16·2–16·6)
19·1% 
(17·8–20·4)
88·5% 
(88·1–88·9)
90·3% 
(89·8–90·8)
Southern Latin America
Argentina 907 
(830–987)
844 
(731–970)
2006 
(1837–2184)
1866 
(1617–2147)
8·5% 
(7·7–9·2)
8·7% 
(7·2–10·5)
85·0% 
(82·3–87·5)
85·4% 
(82·2–88·3)
Chile 1379 
(1311–1460)
1829 
(1712–1955)
2365 
(2248–2504)
3136 
(2937–3353)
9·2% 
(8·7–9·7)
10·7% 
(9·4–12·2)
66·0% 
(63·7–68·1)
70·4% 
(68·1–72·6)
Uruguay 1582 
(1497–1670)
2048 
(1846–2271)
2218 
(2099–2341)
2871 
(2588–3184)
9·3% 
(8·8–9·8)
10·3% 
(8·8–12·1)
82·6% 
(80·9–84·3)
84·5% 
(82·3–86·5)
Western Europe
Andorra 4491 
(4310–4675)
5125 
(4766–5519)
9712 
(9320–10 109)
11 083 
(10 308–11 936)
7·9% 
(7·2–8·6)
9·4% 
(7·6–11·9)
58·6% 
(56·7–60·6)
63·3% 
(60·0–66·4)
Austria 5062 
(4941–5183)
5602 
(5335–5873)
5391 
(5263–5521)
5966 
(5683–6255)
10·4% 
(10·1–10·6)
10·9% 
(10·1–11·7)
80·8% 
(80·0–81·5)
81·8% 
(80·7–82·8)
(Table 2 continues on next page)
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Total health spending per GDP, % Total government health spending and 
prepaid private spending per total 
health spending, %
2017 2030 2017 2030 2017 2030 2017 2030
(Continued from previous page)
Belgium 4595 
(4475–4727)
5387 
(5107–5686)
4995 
(4865–5139)
5857 
(5552–6182)
10·4% 
(10·1–10·7)
11·7% 
(10·9–12·6)
82·3% 
(81·4–83·2)
84·4% 
(83·3–85·5)
Cyprus 1184 
(1111–1261)
1452 
(1350–1566)
1780 
(1671–1897)
2184 
(2031–2355)
5·1% 
(4·0–6·7)
5·5% 
(3·9–8·1)
54·9% 
(52·0–58·2)
58·7% 
(55·3–62·0)
Denmark 5933 
(5782–6079)
6537 
(6302–6768)
5364 
(5227–5496)
5911 
(5698–6119)
10·1% 
(9·9–10·4)
10·6% 
(9·9–11·3)
86·3% 
(85·7–86·9)
87·1% 
(86·4–87·8)
Finland 4386 
(4253–4523)
4894 
(4595–5181)
4298 
(4168–4432)
4796 
(4503–5077)
9·3% 
(9·0–9·6)
9·5% 
(8·8–10·3)
79·6% 
(78·6–80·6)
80·6% 
(79·1–82·0)
France 4530 
(4455–4600)
5127 
(5026–5235)
5100 
(5015–5178)
5772 
(5658–5893)
11·4% 
(11·0–11·8)
12·1% 
(11·2–12·9)
90·6% 
(89·9–91·3)
91·1% 
(90·4–91·8)
Germany 5110 
(4991–5225)
6162 
(5794–6512)
5864 
(5727–5995)
7070 
(6648–7472)
11·1% 
(10·9–11·4)
12·5% 
(11·0–14·1)
87·3% 
(86·7–87·9)
88·7% 
(87·8–89·6)
Greece 1571 
(1477–1676)
1836 
(1664–2020)
2368 
(2227–2526)
2768 
(2509–3046)
8·3% 
(7·8–9·0)
8·7% 
(7·5–10·0)
64·5% 
(61·5–67·5)
66·8% 
(63·3–70·2)
Iceland 5538 
(5290–5805)
5656 
(5264–6079)
4680 
(4470–4905)
4780 
(4448–5137)
8·3% 
(7·9–8·7)
8·5% 
(7·6–9·5)
83·4% 
(82·4–84·5)
83·5% 
(82·0–84·9)
Ireland 4979 
(4718–5249)
6150 
(5670–6662)
5433 
(5148–5728)
6711 
(6187–7270)
7·0% 
(6·6–7·4)
7·0% 
(6·2–8·1)
87·6% 
(86·5–88·6)
87·8% 
(86·5–89·1)
Israel 2961 
(2864–3068)
3711 
(3474–3960)
2710 
(2620–2807)
3396 
(3178–3623)
7·0% 
(6·6–7·4)
7·6% 
(6·6–8·6)
77·4% 
(76·0–78·7)
79·1% 
(77·4–80·8)
Italy 2879 
(2784–2971)
3130 
(2927–3355)
3535 
(3419–3649)
3844 
(3594–4121)
8·8% 
(8·4–9·1)
9·2% 
(8·3–10·4)
76·7% 
(75·3–77·9)
78·0% 
(76·2–79·8)
Luxembourg 6066 
(5714–6448)
6708 
(6057–7439)
5928 
(5584–6301)
6555 
(5918–7268)
5·4% 
(5·1–5·8)
6·0% 
(5·3–6·9)
89·2% 
(87·7–90·6)
90·2% 
(88·5–91·7)
Malta 2831 
(2731–2939)
4020 
(3768–4277)
4353 
(4199–4519)
6182 
(5794–6577)
9·8% 
(9·2–10·4)
11·2% 
(9·9–12·7)
65·0% 
(63·3–66·6)
69·2% 
(67·1–71·5)
Netherlands 5143 
(4950–5341)
6023 
(5611–6462)
5753 
(5537–5974)
6738 
(6277–7228)
10·2% 
(9·8–10·5)
10·8% 
(9·9–11·9)
88·8% 
(87·9–89·7)
89·4% 
(88·3–90·5)
Norway 8102 
(7841–8368)
9313 
(8824–9819)
7959 
(7703–8220)
9148 
(8668–9646)
10·6% 
(10·3–11·0)
11·8% 
(10·6–12·9)
85·8% 
(85·0–86·7)
87·4% 
(86·4–88·3)
Portugal 1889 
(1797–1988)
2127 
(1918–2371)
2744 
(2610–2888)
3089 
(2785–3444)
8·8% 
(8·2–9·6)
9·0% 
(7·7–10·5)
72·5% 
(70·5–74·2)
72·6% 
(69·4–75·9)
Spain 2554 
(2461–2657)
3110 
(2950–3287)
3526 
(3398–3668)
4293 
(4073–4538)
8·9% 
(8·6–9·3)
9·9% 
(8·9–11·0)
76·4% 
(75·1–77·8)
78·4% 
(76·8–80·0)
Sweden 5561 
(5344–5766)
7007 
(6544–7470)
5917 
(5685–6135)
7455 
(6962–7948)
11·0% 
(10·6–11·4)
12·7% 
(11·6–13·8)
84·9% 
(84·0–85·8)
87·3% 
(86·2–88·3)
Switzerland 9903 
(9669–10151)
11 319 
(10796–11888)
7898 
(7711–8095)
9027 
(8610–9481)
12·1% 
(11·8–12·5)
13·5% 
(12·5–14·6)
70·9% 
(70·0–71·8)
73·8% 
(72·3–75·2)
UK 3883 
(3766–4004)
4623 
(4350–4916)
4430 
(4297–4569)
5275 
(4963–5609)
9·6% 
(9·3–9·9)
10·9% 
(9·8–12·1)
84·0% 
(82·8–85·2)
86·0% 
(84·7–87·3)
Latin America 
and Caribbean
589 
(570–611)
704 
(682–729)
1189 
(1150–1234)
1423 
(1377–1476)
7·4% 
(7·1–7·7)
8·1% 
(7·7–8·6)
69·6% 
(67·8–71·4)
72·8% 
(71·1–74·6)
Andean Latin America
Bolivia 217 
(184–258)
288 
(242–346)
443 
(375–525)
587 
(493–705)
6·2% 
(5·3–7·4)
6·8% 
(5·6–8·2)
70·4% 
(62·9–77·2)
73·3% 
(66·5–79·7)
Ecuador 524 
(464–591)
565 
(496–646)
996 
(881–1124)
1074 
(943–1229)
8·2% 
(7·2–9·2)
8·6% 
(7·3–10·1)
59·2% 
(53·9–64·6)
61·6% 
(55·8–67·5)
Peru 330 
(283–384)
434 
(369–514)
687 
(589–799)
903 
(768–1069)
4·9% 
(4·2–5·7)
5·4% 
(4·3–6·6)
70·6% 
(64·7–76·3)
73·5% 
(67·0–79·4)
Caribbean
Antigua and 
Barbuda
668 
(588–750)
909 
(774–1065)
1063 
(935–1194)
1447 
(1232–1694)
4·2% 
(3·6–4·9)
4·8% 
(3·8–5·9)
62·0% 
(56·7–66·8)
65·6% 
(59·4–71·4)
The Bahamas 1990 
(1863–2113)
2144 
(1969–2335)
1967 
(1841–2088)
2119 
(1946–2308)
6·2% 
(5·7–6·8)
6·7% 
(5·6–7·9)
70·8% 
(68·4–73·1)
71·2% 
(68·3–74·1)
(Table 2 continues on next page)
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Barbados 1180 
(1119–1246)
1066 
(989–1152)
1224 
(1160–1291)
1106 
(1025–1195)
6·5% 
(6·1–7·0)
5·9% 
(5·2–6·5)
53·1% 
(50·6–55·6)
46·4% 
(42·5–50·5)
Belize 287 
(247–337)
344 
(297–401)
505 
(435–593)
605 
(522–706)
5·7% 
(5·0–6·7)
5·9% 
(4·8–7·3)
73·7% 
(67·8–78·9)
74·6% 
(68·9–80·4)
Bermuda 7027 
(5973–8208)
8358 
(6986–9870)
4430 
(3765–5174)
5269 
(4404–6222)
6·4% 
(4·7–9·4)
25·3% 
(5·0–18·6)
90·1% 
(86·9–92·8)
91·8% 
(89·1–94·0)
Cuba 1208 
(1129–1304)
1724 
(1566–1899)
3262 
(3050–3522)
4659 
(4231–5131)
11·3% 
(10·1–12·8)
14·5% 
(11·7–18·7)
89·8% 
(87·6–91·7)
91·7% 
(89·7–93·3)
Dominica 493 
(445–550)
644 
(536–774)
699 
(631–780)
915 
(761–1099)
6·6% 
(5·9–7·4)
6·5% 
(5·2–8·0)
68·3% 
(63·3–72·7)
67·5% 
(60·5–73·6)
Dominican 
Republic
436 
(383–493)
714 
(610–828)
1037 
(911–1174)
1698 
(1450–1969)
5·7% 
(5·0–6·5)
6·6% 
(5·3–8·1)
54·5% 
(48·3–60·6)
60·3% 
(53·7–66·6)
Grenada 528 
(474–593)
642 
(553–748)
772 
(692–867)
937 
(808–1093)
5·0% 
(4·5–5·6)
4·9% 
(4·1–6·0)
46·1% 
(40·6–52·0)
46·9% 
(39·7–54·8)
Guyana 258 
(226–299)
621 
(485–793)
456 
(399–528)
1097 
(855–1400)
5·3% 
(4·6–6·1)
6·4% 
(4·8–8·2)
62·6% 
(55·7–69·1)
70·1% 
(61·6–78·1)
Haiti 48 
(40–57)
50 
(42–59)
117 
(99–139)
122 
(102–145)
6·0% 
(5·1–7·2)
6·0% 
(5·0–7·3)
19·3% 
(14·2–25·3)
17·3% 
(11·9–23·6)
Jamaica 329 
(280–389)
395 
(322–482)
583 
(497–690)
700 
(571–855)
6·2% 
(5·3–7·3)
7·0% 
(5·6–8·8)
79·9% 
(74·5–84·5)
81·5% 
(76·0–86·2)
Puerto Rico 1276 
(1101–1487)
1742 
(1499–2034)
1611 
(1390–1878)
2199 
(1892–2568)
4·1% 
(3·4–5·0)
5·4% 
(4·4–6·7)
77·4% 
(69·9–83·6)
81·9% 
(75·5–87·2)
Saint Lucia 549 
(494–609)
685 
(595–781)
743 
(668–824)
926 
(805–1056)
5·0% 
(4·5–5·6)
5·6% 
(4·8–6·6)
51·0% 
(45·9–56·1)
56·6% 
(50·1–62·8)
Saint Vincent 
and the 
Grenadines
335 
(293–382)
439 
(377–507)
532 
(465–606)
696 
(599–806)
4·4% 
(3·9–5·1)
5·0% 
(4·2–5·9)
65·5% 
(59·7–71·7)
67·8% 
(61·1–73·9)
Suriname 414 
(356–477)
526 
(439–637)
1044 
(899–1203)
1328 
(1107–1606)
6·6% 
(5·6–7·6)
7·7% 
(6·1–9·5)
73·4% 
(67·8–78·7)
75·9% 
(69·9–81·2)
Trinidad and 
Tobago
1117 
(1042–1202)
1400 
(1229–1577)
2247 
(2096–2419)
2817 
(2473–3174)
6·8% 
(6·3–7·3)
8·1% 
(6·9–9·5)
59·2% 
(56·0–62·3)
64·5% 
(59·6–69·1)
Virgin Islands 1696 
(1377–2117)
2011 
(1556–2585)
1696 
(1377–2117)
2011 
(1556–2585)
4·2% 
(3·4–5·4)
4·8% 
(3·5–6·7)
75·6% 
(67·3–83·3)
78·0% 
(69·5–84·9)
Central Latin America
Colombia 481 
(416–555)
709 
(605–827)
1147 
(992–1325)
1691 
(1445–1973)
7·6% 
(6·6–8·8)
9·3% 
(7·8–11·2)
83·6% 
(79·0–87·1)
86·2% 
(82·3–89·3)
Costa Rica 944 
(869–1026)
1189 
(1045–1352)
1408 
(1296–1530)
1773 
(1559–2017)
8·1% 
(7·4–8·8)
8·9% 
(7·6–10·3)
78·2% 
(75·0–81·4)
80·3% 
(76·5–83·5)
El Salvador 315 
(275–366)
411 
(355–482)
650 
(568–756)
850 
(733–996)
8·0% 
(6·9–9·4)
9·0% 
(7·5–10·7)
69·8% 
(63·9–75·4)
73·5% 
(68·3–78·7)
Guatemala 265 
(227–311)
322 
(270–382)
493 
(424–580)
600 
(504–712)
5·9% 
(5·0–6·9)
6·0% 
(5·0–7·3)
44·3% 
(36·3–52·8)
48·0% 
(39·9–57·1)
Honduras 185 
(155–218)
229 
(189–275)
387 
(324–457)
479 
(396–576)
7·6% 
(6·3–9·0)
7·7% 
(6·3–9·3)
47·9% 
(39·1–57·0)
50·9% 
(41·9–59·6)
Mexico 562 
(502–629)
641 
(569–721)
1158 
(1035–1297)
1322 
(1172–1486)
5·7% 
(5·0–6·4)
6·1% 
(5·2–7·2)
59·0% 
(54·0–63·8)
62·4% 
(57·0–67·5)
Nicaragua 188 
(161–222)
210 
(180–247)
516 
(441–608)
576 
(492–677)
8·7% 
(7·4–10·3)
10·4% 
(8·5–12·6)
60·3% 
(52·5–67·7)
64·3% 
(56·8–70·9)
Panama 1147 
(1067–1235)
1588 
(1429–1766)
1883 
(1752–2028)
2608 
(2346–2899)
7·4% 
(6·9–8·0)
7·7% 
(6·6–8·9)
68·6% 
(65·6–71·7)
69·2% 
(65·1–73·0)
Venezuela 107 
(89–127)
80 
(64–101)
555 
(466–663)
417 
(334–526)
2·2% 
(1·8–2·8)
2·1% 
(1·6–2·8)
55·1% 
(47·0–63·1)
53·9% 
(43·2–64·3)
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Tropical Latin America
Brazil 799 
(766–834)
942 
(909–978)
1505 
(1443–1570)
1774 
(1712–1841)
9·2% 
(8·8–9·6)
10·1% 
(9·2–11·2)
72·4% 
(69·3–75·3)
75·6% 
(72·8–78·2)
Paraguay 389 
(338–453)
528 
(451–619)
937 
(813–1091)
1271 
(1087–1490)
7·6% 
(6·0–10·0)
8·8% 
(6·5–12·6)
55·8% 
(49·2–62·6)
61·1% 
(54·8–67·4)
North Africa 
and Middle East
353 
(339–367)
426 
(404–451)
1055 
(1012–1104)
1263 
(1198–1337)
5·3% 
(5·1–5·5)
6·4% 
(6·0–6·9)
68·0% 
(66·2–69·8)
72·6% 
(70·8–74·4)
Afghanistan 50 
(37–65)
53 
(40–68)
203 
(154–265)
219 
(165–281)
9·9% 
(7·5–13·0)
9·2% 
(6·6–12·5)
6·7% 
(4·5–9·1)
7·9% 
(5·5–11·1)
Algeria 265 
(232–304)
297 
(249–350)
988 
(866–1133)
1106 
(928–1304)
6·6% 
(5·8–7·6)
7·3% 
(6·1–8·8)
69·1% 
(62·3–75·0)
72·0% 
(65·6–78·1)
Bahrain 1230 
(1169–1292)
1386 
(1287–1483)
2422 
(2300–2543)
2728 
(2534–2920)
4·9% 
(4·7–5·2)
5·9% 
(5·0–6·9)
70·6% 
(68·2–73·1)
74·0% 
(71·0–76·8)
Egypt 147 
(121–178)
189 
(153–228)
675 
(552–815)
863 
(702–1044)
5·5% 
(4·3–6·7)
5·3% 
(4·0–6·7)
39·6% 
(30·3–49·7)
38·4% 
(28·7–49·1)
Iran 555 
(495–618)
580 
(516–648)
1763 
(1574–1966)
1845 
(1642–2061)
8·1% 
(7·2–9·3)
10·1% 
(8·2–12·3)
58·7% 
(53·4–64·4)
65·2% 
(59·8–70·4)
Iraq 195 
(166–230)
258 
(214–306)
609 
(520–719)
808 
(670–958)
3·4% 
(2·9–4·0)
4·0% 
(3·1–5·1)
32·4% 
(26·1–39·0)
41·3% 
(32·4–49·9)
Jordan 293 
(251–344)
348 
(291–427)
643 
(551–754)
764 
(639–938)
6·7% 
(5·8–7·9)
7·2% 
(5·8–8·8)
66·9% 
(60·1–73·3)
69·0% 
(62·1–75·6)
Kuwait 1556 
(1400–1725)
1630 
(1391–1890)
3640 
(3277–4036)
3815 
(3256–4422)
4·9% 
(4·2–5·5)
5·5% 
(4·3–7·0)
85·9% 
(83·6–87·8)
86·4% 
(83·5–88·9)
Lebanon 935 
(847–1028)
1123 
(962–1301)
1481 
(1341–1628)
1777 
(1523–2059)
10·2% 
(8·8–11·9)
10·6% 
(8·2–13·6)
66·5% 
(62·2–70·7)
68·6% 
(63·1–73·7)
Libya 466 
(392–548)
436 
(348–546)
821 
(690–966)
768 
(614–963)
9·5% 
(3·6–20·4)
11·9% 
(3·8–23·1)
73·2% 
(66·4–78·8)
78·0% 
(71·0–84·2)
Morocco 171 
(145–205)
225 
(187–270)
471 
(398–564)
620 
(516–742)
5·3% 
(4·4–6·3)
5·7% 
(4·6–7·0)
44·4% 
(36·3–53·6)
47·6% 
(38·9–57·0)
Oman 664 
(624–711)
626 
(549–731)
1702 
(1600–1822)
1606 
(1406–1875)
4·0% 
(3·5–4·4)
4·0% 
(3·1–5·0)
93·7% 
(92·0–95·0)
93·1% 
(91·1–94·7)
Palestine 365 
(300–436)
492 
(393–615)
139 
(115–167)
188 
(150–235)
10·9% 
(8·9–13·0)
12·1% 
(9·5–15·5)
57·0% 
(48·1–65·9)
63·3% 
(53·6–71·7)
Qatar 1958 
(1780–2155)
3458 
(2762–4411)
3750 
(3410–4128)
6624 
(5291–8451)
2·8% 
(2·6–3·1)
5·0% 
(3·9–6·4)
91·9% 
(90·3–93·3)
94·4% 
(92·6–95·9)
Saudi Arabia 1206 
(1107–1310)
1786 
(1577–2080)
3046 
(2796–3307)
4511 
(3983–5253)
5·2% 
(4·8–5·7)
8·0% 
(6·7–9·7)
83·8% 
(81·7–85·8)
88·8% 
(86·9–90·7)
Sudan 54 
(43–68)
56 
(45–70)
315 
(250–395)
327 
(261–407)
5·8% 
(4·2–8·1)
6·4% 
(4·3–9·4)
26·5% 
(18·9–35·7)
30·5% 
(21·5–40·7)
Syria 57 
(46–70)
75 
(59–91)
922 
(744–1133)
1210 
(958–1478)
5·7% 
(4·3–7·4)
5·9% 
(4·3–8·3)
45·9% 
(35·8–56·6)
48·0% 
(36·9–58·9)
Tunisia 238 
(203–280)
326 
(278–383)
916 
(782–1078)
1253 
(1070–1472)
7·4% 
(6·3–8·7)
9·1% 
(7·6–10·9)
60·6% 
(52·4–68·2)
66·5% 
(59·1–73·9)
Turkey 379 
(333–429)
486 
(403–587)
1228 
(1079–1392)
1578 
(1307–1904)
4·2% 
(3·7–4·8)
4·8% 
(3·9–5·8)
82·2% 
(77·5–86·3)
84·4% 
(79·5–88·2)
United Arab 
Emirates
1485 
(1380–1600)
1925 
(1633–2240)
2630 
(2444–2834)
3408 
(2892–3966)
3·7% 
(3·3–4·1)
5·2% 
(4·1–6·5)
81·1% 
(78·3–83·7)
84·9% 
(81·5–88·0)
Yemen 50 
(42–62)
58 
(48–70)
123 
(101–150)
141 
(116–171)
5·4% 
(3·8–7·5)
5·8% 
(3·9–8·6)
9·6% 
(7·1–12·4)
17·6% 
(13·1–23·5)
South Asia 62 
(51–77)
104 
(85–130)
236 
(192–291)
396 
(321–493)
3·4% 
(2·8–4·2)
3·6% 
(2·8–4·5)
35·3% 
(26·2–45·4)
39·6% 
(29·4–49·4)
Bangladesh 40 
(31–52)
68 
(52–87)
107 
(83–136)
178 
(138–231)
2·5% 
(1·9–3·2)
2·5% 
(1·8–3·4)
21·1% 
(14·9–27·9)
21·4% 
(15·3–28·3)
Bhutan 108 
(90–129)
144 
(109–185)
316 
(262–378)
420 
(320–542)
3·2% 
(2·6–3·9)
2·8% 
(2·0–3·7)
79·2% 
(72·9–84·4)
77·1% 
(68·4–83·9)
(Table 2 continues on next page)
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India 69 
(54–87)
119 
(94–152)
265 
(209–336)
456 
(360–583)
3·5% 
(2·8–4·5)
3·7% 
(2·8–4·8)
36·5% 
(25·6–48·0)
41·1% 
(29·3–52·4)
Nepal 50 
(40–63)
79 
(62–100)
162 
(128–204)
255 
(199–321)
5·5% 
(4·3–7·0)
5·6% 
(4·1–7·4)
31·6% 
(22·7–42·4)
35·7% 
(25·7–47·2)
Pakistan 37 
(29–46)
49 
(38–62)
159 
(126–199)
211 
(164–267)
2·8% 
(2·2–3·5)
2·9% 
(2·2–3·6)
33·0% 
(23·5–43·5)
36·1% 
(25·4–47·2)
Southeast Asia, 
east Asia, 
and Oceania
365 
(329–406)
730 
(645–825)
757 
(686–839)
1499 
(1336–1683)
4·9% 
(4·4–5·5)
6·3% 
(5·3–7·4)
64·2% 
(59·7–68·8)
72·4% 
(67·6–76·7)
East Asia
China 455 
(400–517)
984 
(850–1132)
875 
(769–994)
1891 
(1634–2176)
5·1% 
(4·4–5·7)
6·6% 
(5·4–8·0)
64·5% 
(59·2–69·8)
73·4% 
(67·8–78·2)
North Korea 77 
(60–96)
87 
(68–110)
45 
(35–56)
51 
(39–64)
5·6% 
(4·3–7·0)
5·9% 
(4·4–7·8)
63·8% 
(52·5–73·6)
66·7% 
(55·5–76·0)
Taiwan 
(province of 
China)
1477 
(1312–1677)
1903 
(1677–2172)
3270 
(2905–3711)
4213 
(3713–4808)
6·2% 
(5·5–7·1)
6·9% 
(5·7–8·4)
69·0% 
(64·9–73·7)
72·2% 
(67·9–76·5)
Oceania
American 
Samoa
694 
(572–841)
711 
(573–869)
694 
(572–841)
711 
(573–869)
5·5% 
(4·5–6·8)
6·0% 
(4·7–7·8)
78·4% 
(71·0–85·0)
79·7% 
(72·2–86·3)
Federated 
States of 
Micronesia
141 
(119–166)
224 
(185–270)
136 
(115–160)
215 
(178–259)
4·1% 
(3·3–5·0)
5·9% 
(4·4–7·8)
84·3% 
(80·7–87·5)
88·9% 
(85·8–91·5)
Fiji 198 
(160–243)
255 
(200–322)
356 
(288–438)
459 
(360–580)
3·5% 
(2·7–4·5)
3·8% 
(2·8–5·0)
78·6% 
(71·7–84·5)
79·5% 
(72·5–85·5)
Guam 1468 
(1143–1903)
1607 
(1236–2088)
1468 
(1143–1903)
1607 
(1236–2088)
3·7% 
(2·9–4·9)
4·1% 
(3·1–5·8)
75·1% 
(65·2–83·2)
77·2% 
(68·4–84·6)
Kiribati 214 
(188–246)
234 
(195–282)
290 
(255–334)
317 
(264–382)
14·1% 
(12·2–16·3)
15·0% 
(12·0–18·6)
59·3% 
(52·9–65·3)
61·2% 
(53·0–68·7)
Marshall 
Islands
416 
(370–472)
554 
(468–648)
408 
(362–462)
544 
(459–636)
11·1% 
(9·6–12·9)
12·9% 
(10·4–15·8)
67·2% 
(62·3–71·9)
71·5% 
(65·9–76·7)
Northern 
Mariana 
Islands
752 
(585–992)
806 
(614–1071)
752 
(585–992)
806 
(614–1071)
2·4% 
(1·9–3·2)
2·9% 
(2·1–4·1)
73·4% 
(63·2–81·8)
76·1% 
(66·8–84·1)
Papua New 
Guinea
54 
(44–64)
71 
(57–87)
82 
(67–98)
108 
(87–133)
2·1% 
(1·6–2·5)
2·6% 
(1·9–3·3)
73·5% 
(67·6–78·7)
78·0% 
(72·1–83·0)
Samoa 222 
(194–254)
248 
(209–293)
298 
(259–339)
332 
(280–393)
5·0% 
(4·3–5·7)
5·3% 
(4·2–6·4)
78·7% 
(74·2–82·8)
79·6% 
(74·3–84·2)
Solomon 
Islands
119 
(103–135)
127 
(95–175)
119 
(103–135)
128 
(95–175)
5·6% 
(4·8–6·5)
5·4% 
(3·8–7·6)
60·9% 
(55·2–65·8)
60·6% 
(48·7–72·7)
Tonga 218 
(196–243)
277 
(235–329)
291 
(261–325)
369 
(314–439)
5·1% 
(4·4–5·8)
5·0% 
(3·9–6·3)
65·4% 
(61·2–69·5)
69·3% 
(63·5–74·7)
Vanuatu 98 
(82–118)
117 
(89–154)
89 
(74–107)
107 
(81–140)
3·0% 
(2·5–3·6)
3·1% 
(2·3–4·1)
67·7% 
(61·5–73·4)
70·5% 
(61·5–78·7)
Southeast Asia
Cambodia 83 
(67–101)
129 
(103–157)
236 
(190–288)
368 
(294–448)
5·7% 
(4·6–6·9)
5·8% 
(4·5–7·3)
25·7% 
(19·0–33·6)
28·4% 
(20·6–37·9)
Indonesia 120 
(94–152)
215 
(166–277)
405 
(316–511)
722 
(558–931)
3·2% 
(2·5–4·0)
4·0% 
(3·0–5·2)
60·8% 
(49·1–72·0)
68·7% 
(58·5–77·6)
Laos 58 
(48–70)
83 
(67–103)
173 
(143–210)
247 
(201–309)
2·4% 
(1·9–3·1)
2·3% 
(1·6–3·4)
36·9% 
(28·8–46·7)
36·5% 
(27·4–46·5)
Malaysia 409 
(353–475)
673 
(575–790)
1190 
(1029–1382)
1960 
(1674–2299)
3·9% 
(3·4–4·6)
4·9% 
(4·1–5·9)
62·5% 
(56·6–68·7)
69·0% 
(63·3–75·1)
Maldives 988 
(905–1081)
1638 
(1430–1884)
1479 
(1355–1618)
2452 
(2141–2821)
8·1% 
(6·4–10·1)
10·6% 
(7·4–14·8)
79·7% 
(76·5–82·7)
83·9% 
(80·4–86·9)
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Mauritius 606 
(541–677)
969 
(855–1106)
1309 
(1170–1462)
2094 
(1846–2389)
5·7% 
(5·1–6·4)
6·9% 
(5·9–8·2)
50·9% 
(45·7–56·3)
57·9% 
(52·2–63·5)
Myanmar 52 
(41–66)
87 
(68–111)
279 
(220–357)
470 
(365–597)
4·4% 
(3·4–5·6)
4·4% 
(3·3–5·9)
16·3% 
(11·4–22·1)
18·6% 
(11·5–27·0)
Philippines 133 
(107–168)
204 
(165–256)
374 
(300–472)
573 
(463–719)
4·4% 
(3·5–5·6)
4·8% 
(3·8–6·2)
44·5% 
(34·6–55·8)
50·0% 
(39·3–61·6)
Sri Lanka 152 
(124–182)
204 
(164–247)
534 
(437–641)
718 
(579–871)
3·9% 
(3·2–4·8)
4·1% 
(3·2–5·1)
48·8% 
(39·4–58·4)
49·2% 
(38·9–59·2)
Seychelles 754 
(697–817)
992 
(846–1161)
1394 
(1288–1510)
1834 
(1563–2146)
4·6% 
(4·3–5·0)
5·0% 
(4·2–6·0)
74·3% 
(70·8–77·8)
76·7% 
(72·2–81·3)
Thailand 271 
(229–326)
388 
(326–465)
702 
(593–843)
1005 
(844–1205)
3·8% 
(3·2–4·5)
4·4% 
(3·6–5·4)
88·1% 
(84·1–91·4)
89·7% 
(86·1–92·7)
Timor-Leste 86 
(69–106)
114 
(89–144)
197 
(158–243)
261 
(204–331)
3·6% 
(2·9–4·4)
4·0% 
(3·0–5·3)
72·5% 
(66·0–78·6)
77·7% 
(71·0–83·6)
Vietnam 135 
(111–164)
208 
(167–257)
399 
(327–484)
614 
(492–758)
5·5% 
(4·5–6·7)
5·6% 
(4·3–7·3)
52·6% 
(43·5–62·7)
53·6% 
(43·7–64·5)
Sub-Saharan 
Africa
81 
(75–87)
92 
(85–99)
204 
(190–218)
232 
(216–250)
5·2% 
(4·8–5·6)
5·1% 
(4·7–5·6)
54·0% 
(50·6–57·2)
55·8% 
(52·0–59·5)
Central sub-Saharan Africa
Angola 90 
(73–112)
82 
(64–105)
205 
(166–254)
186 
(145–238)
2·9% 
(2·3–3·6)
2·7% 
(2·0–3·5)
62·6% 
(52·7–72·2)
58·6% 
(46·8–70·2)
Central 
African 
Republic
21 
(18–23)
26 
(22–31)
36 
(32–41)
45 
(38–54)
4·7% 
(4·0–5·6)
4·7% 
(3·6–6·0)
14·6% 
(10·9–19·1)
21·0% 
(12·7–32·0)
Congo 
(Brazzaville)
59 
(48–71)
64 
(49–84)
175 
(143–210)
191 
(147–248)
2·7% 
(2·0–3·5)
2·6% 
(1·7–3·7)
46·8% 
(36·3–56·2)
44·4% 
(32·7–56·9)
Democratic 
Republic of 
the Congo
19 
(16–22)
21 
(17–26)
30 
(26–36)
35 
(28–42)
3·7% 
(3·0–4·5)
3·7% 
(2·6–4·9)
20·5% 
(13·6–29·5)
24·2% 
(16·1–34·9)
Equatorial 
Guinea
299 
(257–345)
352 
(304–409)
711 
(611–821)
837 
(723–972)
2·8% 
(2·4–3·2)
3·1% 
(2·3–4·1)
20·9% 
(16·1–26·9)
29·2% 
(22·7–37·5)
Gabon 289 
(253–338)
386 
(328–460)
702 
(612–819)
936 
(795–1115)
3·6% 
(3·2–4·2)
4·3% 
(3·5–5·3)
65·6% 
(59·6–71·4)
70·6% 
(64·3–76·3)
Eastern sub-Saharan Africa
Burundi 30 
(26–36)
31 
(26–39)
70 
(60–84)
74 
(60–93)
9·0% 
(7·5–10·9)
9·4% 
(7·4–12·0)
35·5% 
(26·3–46·7)
37·7% 
(26·4–50·7)
Comoros 74 
(60–91)
85 
(70–104)
150 
(122–185)
173 
(142–211)
5·2% 
(4·0–6·5)
5·3% 
(4·0–7·0)
14·9% 
(10·4–20·4)
19·5% 
(13·3–26·8)
Djibouti 57 
(48–69)
63 
(51–79)
104 
(87–124)
113 
(92–142)
2·5% 
(1·7–3·6)
2·4% 
(1·5–3·7)
56·8% 
(47·8–65·0)
55·6% 
(44·6–66·2)
Eritrea 24 
(20–30)
33 
(26–40)
33 
(27–41)
44 
(35–54)
5·2% 
(2·7–10·2)
5·8% 
(2·3–17·2)
21·9% 
(16·0–28·8)
26·8% 
(17·9–37·1)
Ethiopia 31 
(25–38)
43 
(34–57)
81 
(67–101)
114 
(89–149)
4·0% 
(3·1–5·1)
3·3% 
(2·3–4·7)
39·4% 
(28·8–51·5)
45·8% 
(33·3–58·9)
Kenya 96 
(78–120)
126 
(100–161)
185 
(150–230)
243 
(192–310)
5·3% 
(4·3–6·7)
5·1% 
(3·9–6·7)
54·1% 
(43·3–63·5)
60·1% 
(49·6–69·8)
Madagascar 22 
(18–27)
28 
(22–36)
81 
(65–100)
102 
(80–130)
4·8% 
(3·7–6·0)
5·3% 
(3·9–7·1)
58·1% 
(48·7–67·8)
64·7% 
(54·5–74·1)
Malawi 45 
(41–51)
46 
(40–55)
151 
(136–169)
154 
(132–184)
11·9% 
(10·5–13·7)
9·7% 
(7·8–12·3)
29·1% 
(22·5–37·2)
34·3% 
(25·5–44·4)
Mozambique 34 
(32–36)
36 
(32–42)
91 
(85–98)
98 
(85–114)
6·9% 
(6·4–7·4)
5·1% 
(4·2–6·2)
23·7% 
(19·5–28·9)
35·5% 
(27·4–44·4)
Rwanda 45 
(39–53)
60 
(46–78)
133 
(114–157)
175 
(136–229)
6·2% 
(5·3–7·4)
5·3% 
(3·9–7·3)
46·2% 
(37·4–54·9)
63·8% 
(53·8–73·5)
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Somalia 6 
(5–7)
6 
(5–8)
14 
(12–16)
14 
(12–17)
4·7% 
(3·9–5·6)
4·7% 
(3·8–5·9)
19·3% 
(14·7–24·9)
19·3% 
(14·2–25·0)
South Sudan 32 
(29–35)
29 
(25–33)
217 
(201–237)
197 
(173–229)
9·7% 
(6·1–13·2)
7·5% 
(3·3–11·9)
14·5% 
(10·9–19·0)
18·5% 
(15·2–22·1)
Tanzania 43 
(38–49)
50 
(41–61)
129 
(115–147)
151 
(124–185)
4·2% 
(3·5–5·1)
3·8% 
(2·7–5·7)
35·7% 
(29·0–43·5)
44·7% 
(34·7–55·0)
Uganda 44 
(37–51)
54 
(44–64)
149 
(127–173)
184 
(151–219)
6·5% 
(5·4–7·8)
5·9% 
(4·5–7·6)
19·5% 
(13·9–25·9)
30·1% 
(21·6–40·2)
Zambia 66 
(58–76)
67 
(55–83)
210 
(182–241)
212 
(173–264)
5·0% 
(4·3–5·8)
4·7% 
(3·7–6·0)
40·8% 
(33·2–49·1)
44·0% 
(33·2–56·0)
Southern sub-Saharan Africa
Botswana 449 
(393–516)
738 
(633–859)
1017 
(890–1170)
1671 
(1433–1946)
5·9% 
(5·1–6·8)
7·5% 
(6·1–9·1)
89·6% 
(87·8–91·4)
93·0% 
(91·3–94·4)
eSwatini 289 
(249–340)
327 
(270–399)
773 
(666–909)
873 
(722–1067)
7·1% 
(6·1–8·3)
6·9% 
(5·6–8·5)
59·2% 
(52·5–65·7)
58·9% 
(50·7–67·7)
Lesotho 129 
(113–147)
172 
(148–199)
336 
(296–383)
448 
(387–519)
10·5% 
(9·0–12·3)
12·0% 
(9·6–15·0)
53·4% 
(47·2–59·6)
58·4% 
(51·1–65·0)
Namibia 553 
(488–629)
630 
(546–729)
1100 
(971–1252)
1253 
(1085–1450)
9·4% 
(8·2–10·9)
10·1% 
(8·2–12·4)
83·8% 
(80·6–86·6)
84·7% 
(81·2–87·5)
South Africa 533 
(466–612)
673 
(573–793)
1195 
(1044–1372)
1509 
(1285–1777)
8·6% 
(7·5–9·9)
10·5% 
(8·9–12·4)
89·9% 
(87·2–92·2)
91·4% 
(89·0–93·4)
Zimbabwe 75 
(62–92)
71 
(56–91)
285 
(235–349)
270 
(213–347)
9·0% 
(6·5–12·8)
8·3% 
(5·5–12·8)
54·1% 
(44·9–63·2)
51·1% 
(39·1–62·8)
Western sub-Saharan Africa
Benin 35 
(29–41)
41 
(33–51)
97 
(81–116)
114 
(92–143)
3·7% 
(2·6–4·9)
3·2% 
(2·1–4·8)
27·8% 
(20·4–36·9)
33·0% 
(24·2–43·7)
Burkina Faso 41 
(33–49)
55 
(43–68)
116 
(95–141)
156 
(122–194)
6·0% 
(5·0–7·3)
6·0% 
(4·7–7·6)
47·3% 
(36·7–57·3)
54·7% 
(43·9–65·4)
Cameroon 60 
(48–75)
75 
(59–95)
158 
(125–198)
196 
(155–248)
4·1% 
(3·2–5·1)
3·9% 
(3·0–5·0)
15·9% 
(10·8–22·2)
17·9% 
(11·5–26·0)
Cape Verde 162 
(135–194)
237 
(191–292)
349 
(291–417)
509 
(411–627)
4·8% 
(4·0–5·7)
5·3% 
(4·2–6·5)
67·1% 
(58·8–74·3)
70·8% 
(61·8–77·9)
Chad 29 
(23–37)
32 
(25–41)
83 
(66–106)
93 
(72–118)
3·9% 
(2·8–5·3)
3·7% 
(2·5–5·1)
24·9% 
(17·5–33·3)
27·3% 
(18·1–38·7)
Côte d’Ivoire 74 
(58–92)
98 
(76–128)
195 
(153–241)
259 
(200–336)
4·8% 
(3·8–5·9)
4·6% 
(3·4–6·0)
44·5% 
(33·1–57·1)
49·3% 
(36·5–61·5)
The Gambia 43 
(40–47)
42 
(37–49)
162 
(151–176)
158 
(138–183)
7·1% 
(5·1–10·6)
5·3% 
(3·3–8·9)
20·3% 
(16·1–25·9)
20·5% 
(15·7–26·7)
Ghana 66 
(53–81)
111 
(87–138)
208 
(168–254)
349 
(275–434)
3·7% 
(2·7–5·3)
4·4% 
(2·9–6·6)
46·5% 
(36·0–57·0)
58·8% 
(47·9–69·5)
Guinea 45 
(36–55)
60 
(47–77)
110 
(90–135)
149 
(116–188)
4·4% 
(3·4–5·8)
4·2% 
(3·0–5·9)
23·7% 
(15·6–33·5)
29·7% 
(19·6–41·7)
Guinea-
Bissau
60 
(49–73)
71 
(56–89)
142 
(116–172)
168 
(132–211)
8·3% 
(6·7–10·3)
7·9% 
(6·1–10·2)
10·5% 
(6·9–15·0)
14·1% 
(8·7–20·6)
Liberia 65 
(56–75)
74 
(62–88)
130 
(112–151)
148 
(124–177)
10·6% 
(7·6–15·3)
11·2% 
(7·1–18·7)
17·8% 
(12·2–25·2)
20·7% 
(13·1–30·6)
Mali 32 
(27–37)
38 
(31–46)
85 
(73–100)
102 
(83–125)
3·4% 
(2·6–4·3)
3·2% 
(2·2–4·3)
31·1% 
(24·1–39·1)
40·2% 
(29·8–51·7)
Mauritania 61 
(50–74)
80 
(65–99)
213 
(175–257)
279 
(226–345)
5·0% 
(4·0–6·2)
4·8% 
(3·6–6·2)
40·5% 
(31·1–50·2)
43·0% 
(33·1–54·0)
Niger 26 
(21–33)
33 
(26–41)
69 
(56–86)
87 
(68–108)
6·8% 
(5·5–8·5)
7·0% 
(5·3–9·0)
30·6% 
(22·3–39·9)
40·5% 
(30·2–51·2)
Nigeria 78 
(62–96)
85 
(68–107)
212 
(170–262)
233 
(185–291)
3·5% 
(2·8–4·3)
3·4% 
(2·6–4·4)
16·0% 
(11·2–21·6)
17·4% 
(11·2–25·5)
(Table 2 continues on next page)
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prepaid private sources increased from $140·6 million 
(26·9–430·0) in 2000 to $395·8 million (93·2–1166·8) 
in 2017.
Since 2015, spending in low-income and middle-
income countries to prevent and treat HIV/AIDS has 
increased from $10·6 billion (95% UI 8·3–13·9) to 
$12·0 billion (9·1–16·2) in 2017, primarily due to 
increases in government spending. Despite this growth, 
increases in spending levels have not been even across 
countries. 39 countries (including Zimbabwe and Kenya) 
spent less on HIV/AIDS in 2017 than in 2015, primarily 
because of reductions in DAH; a full list of country 
estimates is on the Global Health Data Exchange website.
The amount of HIV/AIDS spending per prevalent 
case for each region in 2017, and the fraction that is 
from each financing source is shown in figure 1B. 
Although more was spent in total in sub-Saharan Africa 
($7660·6 million [95% UI 6736·2–8883·6]), HIV/AIDS 
spending per prevalent case was highest in the GBD 
super-region north Africa and the Middle East ($2987 
[95% UI 1857–4589] per prevalent case), followed by Latin 
American and the Caribbean ($1702 [1113–2640] per 
prevalent case). Per prevalent case, spending was lowest 
in south Asia ($297 [216–413] per prevalent case) and 
sub-Saharan Africa ($296 [263–338] per prevalent case). 
Although domestic governments contributed the most 
to spending on HIV/AIDS in most regions, financing 
was dominated in sub-Saharan Africa by DAH (54·9% 
[48·0–61·5] of total HIV/AIDS spending; figure 1B).
SDG indicator 3.3.1 is to eliminate HIV/AIDS incidence. 
Change in HIV/AIDS incidence and HIV/AIDS spending 
per capita for each low-income and middle-income 
country for 2000–17 is shown in figure 1C. For all but 
one (Venezuela) of 135 countries, HIV/AIDS spending 
per capita has increased since 2000. 73 countries had 
reductions in HIV/AIDS incidence, while 62 had increases 
in incidence. While sub-Saharan Africa has had major 
decreases in HIV incidence and increases in spending 
per capita, other super-regions have had increases in 
HIV incidence since 2015.
Total tuberculosis spending disaggregated by source 
in 135 low-income and middle-income countries for 
2000–17 is shown in figure 2A. These countries comprise 
98·4% (95% UI 98·3–98·4) global tuberculosis incidence 
in 2017 and 98·7% (98·7–98·8) of tuberculosis deaths 
for the same year.23,38 For these countries, spending on 
tuberculosis increased at an annualised rate of 3·87% 
(3·04–4·64), from $5·7 billion (5·2–6·5) in 2000 to 
$10·9 billion (10·3–11·8) in 2017. Government spending 
amounted to $6·9 billion (6·5–7·5) or 63·5% (59·2–66·8) 
of all tuberculosis spending in 2017 and increased 
annually by 5·06% (4·43 to 5·72) since 2000. Although 
DAH for tuberculosis increased at an even faster 
rate (15·91%), the amount in 2017 was $1·7 billion, of 
which 33·5% was spent on administrative costs and 
global initiatives. The amount of tuberculosis spending 
that was out-of-pocket has decreased steadily since 2000, 
as more tuberculosis cases have been treated in the public 
system. In 2000, an estimated $2·4 billion (1·9–3·1) was 
spent out-of-pocket on tuberculosis, while in 2017, $2·1 bil-
lion (1·6–2·7) was spent. Spending on tuberculosis from 
prepaid private sources was $246·9 million (171·9–368·7) 
in 2000 and $225·0 million (184·1–280·7) in 2017. Since 
the start of the SDGs in 2015, 87 of 135 low-income and 
middle-income countries we analysed increased their 
spending on tuberculosis (for more details see the WHO 
Global Health Data Exchange).
The amount of tuberculosis spending per incident 
case for each GBD super-region in 2017 (excluding 
the high-income region), and the fraction that is from 
each financing source are shown in figure 2B. Total 
spending was greatest in the central Europe, eastern 
Europe, and central Asia (appendix p 10), which also had 
the largest spending per incident case ($13 955 [95% UI 
12 659–15 341]). The lowest spending per incident case was 
in sub-Saharan Africa ($526 [493–569]) and south Asia 
($616 [489–787]). In most super-regions in 2017, domestic 
governments were the source of more than 75% of total 
tuberculosis funding. In south Asia, the dominant sources 
of spending were governments (44·1% [32·3–54·8]) and 
Health spending per capita, 2019 US$ Health spending per capita, 2019 
purchasing-power parity-adjusted $
Total health spending per GDP, % Total government health spending and 
prepaid private spending per total 
health spending, %
2017 2030 2017 2030 2017 2030 2017 2030
(Continued from previous page)
São Tomé and 
PrÍncipe
113 
(100–128)
136 
(103–181)
184 
(162–208)
221 
(167–295)
5·8% 
(5·0–6·6)
5·6% 
(4·1–7·6)
46·3% 
(39·3–52·9)
50·5% 
(37·3–65·0)
Senegal 65 
(55–78)
76 
(62–92)
170 
(142–203)
197 
(161–240)
4·8% 
(4·0–5·8)
4·4% 
(3·5–5·4)
29·2% 
(22·1–37·2)
30·8% 
(22·4–41·3)
Sierra Leone 70 
(58–84)
82 
(67–101)
223 
(185–268)
260 
(213–322)
13·5% 
(11·2–16·3)
12·5% 
(9·8–16·0)
21·1% 
(14·1–29·9)
22·1% 
(14·2–31·9)
Togo 41 
(33–51)
54 
(43–69)
111 
(89–137)
147 
(116–186)
6·4% 
(5·1–7·9)
6·6% 
(5·2–8·5)
26·3% 
(18·2–35·8)
34·8% 
(24·5–46·0)
Estimates in parentheses are 95% uncertainty intervals. Venezuela estimates are presented as 2014 US$. GBD=Global Burden of Diseases, Injuries, and Risk Factors study. GDP=Gross Domestic Product.
Table 2: Total health spending, by World bank income group, and GBD super-region, 2017 and 2030
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Figure 1: HIV/AIDS spending 
in low-income and middle-
income countries
(A) Total spending on HIV/AIDS 
by financing source, 
2000 to 2017. (B) Breakdown 
of financing sources of 
HIV/AIDS spending and total 
HIV/AIDS spending per 
prevalent case, by GBD super-
region, in 2017 with pie size 
proportional to spending per 
prevalent case of HIV/AIDS. 
(C) Annualised rates of change 
in HIV/AIDS prevalence and 
HIV/AIDS spending per capita, 
with each arrow showing one 
country moving from 2000 to 
2017. Data are from all World 
Bank low-income and middle-
income countries and spending 
estimates are presented in 
2019 $US. Venezuela’s 
spending is presented in 
2014 $US. Administrative 
expenses that are only shown 
in panel A and reflect the 
operational expense of 
deploying the grant that is 
accrued in the donor country 
(eg, salaries of headquarters 
office staff). AFG=Afghanistan. 
ARM=Armenia. 
AZE=Azerbaijan. 
BFA=Burkina Faso. 
BLR=Belarus. BWA=Botswana. 
CHN=China. CMR=Cameroon. 
COM=Comoros. CUB=Cuba. 
DZA=Algeria. FSM=Federated 
States of Micronesia. 
GAB=Gabon. GBD=Global 
Burden of Diseases, Injuries, 
and Risk Factors study. 
GEO=Georgia. 
GMB=The Gambia. 
KHM=Cambodia. LBR=Liberia. 
MHL=Marshall Islands. 
MMR=Myanmar. 
MNG=Mongolia. 
MOZ=Mozambique. 
MUS=Mauritius MWI=Malawi. 
NER=Niger. PAK=Pakistan. 
RUS=Russia. RWA=Rwanda. 
SWZ=eSwatini. TJK=Tajikistan. 
TLS=Timor-Leste. 
VEN=Venezuela. YEM=Yemen. 
ZWE=Zimbabwe.
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Figure 2: Tuberculosis 
spending in low-income and 
middle-income countries
(A) Spending on tuberculosis 
by financing source, 
2000 to 2017. (B) Breakdown 
of financing sources of 
tuberculosis spending and 
total tuberculosis spending for 
each incident case, by GBD 
super-region, in 2017, with pie 
size proportional to spending 
per prevalent case of 
tuberculosis. (C) Annualised 
rates of change in tuberculosis 
incidence and tuberculosis 
spending per capita, with each 
arrow showing one country 
moving from 2000 to 2017. 
Data are from all World Bank 
low-income and middle-
income countries and 
spending estimates are 
presented in 2019 US$. 
Venezuela’s spending is 
presented in 2014 US$. 
Administrative expenses that 
are only shown in panel A 
reflect the operational expense 
of deploying the grant that is 
accrued in the donor country 
(eg, salaries of headquarters 
office staff). ALB=Albania. 
ARM=Armenia. 
AZE=Azerbaijan. 
BGR=Bulgaria. BLR=Belarus. 
CHN=China. CIV=Côte d'Ivoire. 
CRI=Costa Rica. CUB=Cuba. 
DZA=Algeria. ECU=Ecuador. 
ERI=Eritrea. GAB=Gabon. 
GBD=Global Burden of 
Diseases, Injuries, and Risk 
Factors study. GNB=Guinea-
Bissau. GRD=Grenada. 
GTM=Guatemala. IRQ=Iraq. 
JOR=Jordan. KAZ=Kazakhstan. 
LBY=Libya. LKA=Sri Lanka. 
LSO=Lesotho. MDA=Moldova. 
MKD=North Macedonia. 
MMR=Myanmar. 
MOZ=Mozambique. 
MRT=Mauritania. 
NAM=Namibia. NER=Niger. 
NGA=Nigeria. NIC=Nicaragua. 
PAK=Pakistan. PER=Peru. 
PHL=Philippines. 
PNG=Papua New Guinea. 
PRK=North Korea. RUS=Russia. 
RWA=Rwanda. SSD=South 
Sudan. STP=São Tomé and 
Príncipe. SWZ=eSwatini. 
TCD=Chad. TJK=Tajikistan. 
TLS=Timor-Leste. TUR=Turkey. 
VEN=Venezuela. YEM=Yemen.
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out-of-pocket spending (42·8% [30·0–56·8]), while in 
sub-Saharan Africa, governments (39·0% [35·4–42·7]) 
and DAH (28·8% [26·6–30·7]) are the main sources of 
funding for tuberculosis.
SDG indicator 3.3.2 is to eliminate tuberculosis inci-
dence. Change in tuberculosis incidence and tuberculosis 
spending per capita for each low-income and middle-
income country for 2000–17 is shown in figure 2C. 
122 (90%) of 135 low-income and middle-income countries 
saw decreases in tuberculosis incidence between 2000 
and 2017, with the few exceptions being primarily in 
sub-Saharan Africa and southeast Asia, east Asia, and 
Oceania. We saw substantial variation in spending patterns 
over time, with 113 (84%) of 135 countries increasing 
spending and 22 (16%) countries decreasing tuberculosis 
spending per capita. For tuberculosis, in eSwatini, Lesotho, 
and Nicaragua, we observed a more than 12% annualised 
rate of change in per capita spending with varying 
annualised rates of change in incidence (0·89% decrease 
for eSwatini, 0·04% increase for Lesotho, 2·14% decrease 
for Nicaragua; figure 2C).
Total malaria spending disaggregated by financing 
source in 106 countries with local malaria transmis-
sion since 2000 is shown in figure 3A. 102 (96%) of 
106 countries are low-income or middle-income coun-
tries, and 99·98% (95% UI 99·97–99·98) of malaria 
deaths in 2017 were in these 106 countries.38 Spending 
on malaria increased annually by 7·96% (95% UI 
8·20–7·74) from $1·4 billion (1·3–1·5) in 2000 to 
$5·1 billion (4·9–5·4) in 2017. Domestic govern ments 
have been a relatively stable source of funding for 
malaria, with spending changing from $0·8 billion 
(0·7–0·9) in 2000 to $1·6 billion (1·5–1·8) in 2017. 
Meanwhile, spending from DAH and out-of-pocket 
spending have substantially increased, comprising 
48·7% (46·3–50·8) and 16·1% (13·4–19·8) of total 
spending in 2017. DAH contributed $2·5 billion in 2017, 
while $0·8 billion (0·7–1·0) was contributed by out-of-
pocket spending.
Since 2015, spending on malaria increased from 
$4·8 bil lion (95% UI 4·6–5·1) to $5·1 billion (4·9–5·4) in 
2017, and spending in 63 (59%) of 106 countries increased 
(figure 3). Increases in prepaid-private spending, out-of-
pocket spending, and DAH all contributed to these 
increases.
The amount of malaria spending per capita for each 
region in 2017 and the fraction that is from each 
financing source are shown in figure 3B. The spending 
per capita in sub-Saharan Africa was $3·21 (95% UI 
3·01–3·44), which was much larger than in the other 
malaria endemic GBD super-regions. The least spending 
per capita was in central Europe, eastern Europe, and 
central Asia ($0·10 [0·08–0·13]). Govern ment spending 
constitutes the most spending on malaria in the super-
regions of central Europe, eastern Europe, and central 
Asia; Latin America and Caribbean; north Africa and the 
Middle East; and southeast Asia, east Asia, and Oceania. 
DAH made up a larger share of the spending on malaria 
for sub-Saharan Africa than the other communicable 
diseases tracked in this study.
SDG indicator 3·3.3 is to eliminate malaria incidence. 
Change in malaria incidence and malaria spending 
per capita for each of 102 malaria endemic low-income 
and middle-income country for 2000–17 are shown in 
figure 3C. This figure highlights the 13 of 102 countries 
that have eliminated malaria since 2000 and relatively 
constant malaria spending per capita. Additionally, 
all but three of the remaining 93 remaining malaria 
endemic low-income and middle-income countries—
Djibouti, Niger, and Venezuela—have seen reductions 
in malaria incidence. Meanwhile, malaria spending per 
capita has increased in 78 of 106 malaria endemic low-
income and middle-income countries with the largest 
spending increases in sub-Saharan Africa. We observed 
that in Myanmar and eSwatini, per capita spending 
increased at an annualised rate of more than 15% 
from 2000 to 2017, and annualised incidence rate of 
the disease decreased by more than 10% (figure 3C).
Change in universal health coverage service coverage 
index and pooled health spending per capita for 2000–17 
across all 195 countries and territories is shown in 
figure 4. We saw a strong association between increases 
in pooled health spending per capita and progress 
towards universal health coverage, with countries in the 
GBD super-regions of sub-Saharan Africa, south Asia, 
and southeast Asia, east Asia and Oceania making large 
gains in universal health coverage as pooled spending 
per capita increased. Since 2015, spending increased 
in 166 (85%) of 195 countries and universal health ser-
vice coverage increased in 188 (96%) countries (data not 
shown).
Although economic development is associated with 
reducing the domestic health financing burden that is 
funded by out-of-pocket spending, considerable variation 
exists in this association (figure 5A). For any one level 
of GDP per capita, a sizeable range of the fraction of 
domestic health spending is financed by out-of-pocket 
spending, suggesting that economic development does 
not solely determine the transition away from household 
financing. Additionally, large variation exists across 
countries in the association between rate of change in the 
fraction of domestic health spending that is out-of-pocket 
and the rate of change in the proportion of house-
holds with catastrophic health expenditure (figure 5B). 
A reliance on domestic government, prepaid, and pooled 
health financing is a means towards achieving universal 
health coverage and financial risk protection. Globally, 
this fraction contributing to universal health coverage 
ranges from 6·7% (95% UI 4·5–9·1) in Afghanistan to 
100% (100–100) in Greenland (for more details see the 
WHO Global Health Data Exchange).
In 2019, $40·6 billion of DAH was disbursed and 
increased at an annualised rate of 1·74% since 2015 
(figure 6A). Over 1990 to 2019, reproductive and 
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Figure 3: Malaria spending in 
106 malaria endemic 
countries
(A) Total spending on malaria 
by financing source, 
2000 to 2017. (B) Breakdown 
of financing source of malaria 
spending and the total malaria 
spending for each incident 
case, by GBD super-region, 
in 2017, with pie size 
proportional to spending per 
prevalent case of malaria. 
(C) Annualised rates of change 
in malaria incidence and 
malaria spending per capita, 
with each arrow showing one 
country moving from 
2000 to 2017. Data are from all 
malaria-endemic World Bank 
low-income and middle-
income countries and spending 
estimates are presented in 
2019 US$. Venezuela’s 
spending is presented in 
2014 US$. Administrative 
expenses are only shown in 
panel A reflect the operational 
expense of deploying the grant 
that is accrued in the donor 
country (eg, salaries of 
headquarters office staff). 
In panel C, dashed lines indicate 
countries that have eliminated 
malaria. World Bank low- and 
middle-income countries that 
have eliminated malaria since 
2000 are Argentina, Armenia, 
Azerbaijan, Costa Rica, Georgia, 
Iraq, Kyrgyzstan, Morocco, 
Paraguay, Sri Lanka, Syria, 
Tajikistan, Turkey, and 
Uzbekistan. AFG=Afghanistan. 
BGD=Bangladesh. 
BTN=Bhutan. BWA=Botswana. 
CHN=China. COL=Colombia. 
COM=Comoros. 
CPV=Cape Verde. DJI=Djibouti. 
DZA=Algeria. ETH=Ethiopia. 
GBD=Global Burden of 
Diseases, Injuries, and Risk 
Factors study. 
GMB=The Gambia. 
GNB=Guinea-Bissau. 
GTM=Guatemala. 
HND=Honduras. 
KHM=Cambodia. LBR=Liberia. 
MMR=Myanmar. 
MYS=Malaysia. NER=Niger. 
NPL=Nepal. PHL=Philippines. 
PRK=North Korea. 
SLV=El Salvador. 
SOM=Somalia. STP=São Tomé 
and PrÍncipe. SWZ=eSwatini. 
THA=Thailand. TLS=Timor-
Leste. VEN=Venezuela. 
YEM=Yemen.
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maternal health has consis tently received substantial 
contributions, starting from $1·7 billion in 1990 to 
$4·8 billion in 2019. This change constitutes an 
annualised rate of change of 3·65%. However, since in 
2004, DAH for HIV/AIDS has received the highest 
contributions of all health focus areas, peaking at 
$12·0 billion in 2012.
The annualised rate of change across the health focus 
areas for the time periods associated with the Millennium 
Development Goals (MDGs) and the SDGs are shown in 
figure 6B. Between 2000 and 2015, DAH increased by 
7·75%, with disburse ments for malaria increasing by 
18·32%, for tuberculosis by 16·18%, and for HIV/AIDS 
by 13·02% . For the period 2015–19, the annu alised 
growth rate for tuberculosis spending is 5·75%, for 
HIV/AIDS is 2·18%, and for malaria is 1·43%. Other 
key health focus areas that are funding progress on 
specific SDG indi cators have had annual rates of change 
for 2015–19 of 4·25% for non-communicable diseases, 
2·53% for reproductive and maternal health, and 0·66% 
for newborn and child health. The annu alised growth 
rate of DAH for other infectious diseases has decreased 
for the period 2015–19, which is driven by the increased 
contributions that went towards the Ebola outbreak in 
2014–15 and the subsequent re-alignment of resources 
after the Ebola crisis.
Based on past trends and associations, we estimate 
that an additional $238 (95% UI 209–267) per capita will 
be available for health globally in 2030 compared with 
2017, with persistent disparities in spending between 
countries and across income groups (table 2). The 
proportion of health spending from pooled sources is 
expected to increase from 81·6% (81·6–81·7) in 2015 to 
83·1% (82·8–83·3) in 2030. In high-income countries, 
health spending is expected to continue to increase, with 
expected annualised growth rates of 1·93% (1·77–2·10), 
reaching $6596 (6482–6708) per capita in 2030. For 
high-income countries, government and prepaid private 
spending as the financing sources of health is expected 
to increase to 87·8% (87·5–88·1) of total health 
spending. Health spending growth is expected to be 
fastest in lower-middle-income countries, where the 
Figure 4: Annualised rate of change in universal health service coverage index and annualised rate of change in pooled health spending per capita, 2000 to 2017
Data are for 195 countries in territories, by GBD super-region. Spending estimates are presented in 2019 US$, and pooled health spending is the sum of government 
spending, prepaid private spending, and development assistance for health. Each arrow shows one country moving from 2000 to 2017. Spending estimates are 
presented in 2019 US$. AFG=Afghanistan. AZE=Azerbaijan. CHN=China. COD=Democratic Republic of the Congo. ERI=Eritrea. ETH=Ethiopia. GBD=Global Burden of 
Diseases, Injuries, and Risk Factors study. GEO=Georgia. GUM=Guam. KHM=Cambodia. LAO=Laos. LSO=Lesotho. MMR=Myanmar. RWA=Rwanda. TCD=Chad. 
TLS=Timor-Leste. VEN=Venezuela. YEM=Yemen.
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annual growth rate is expected to be 4·38% (4·13–4·66) 
between 2018 and 2030, with per-capita spending 
reaching $127 (114–141). In these countries, government 
spending is also expected to be the financing source with 
the fastest growth (5·12% [4·73–5·54]), with govern-
ment and prepaid private health spending making up 
45·7% (40·1–51·0) of overall spending. For countries 
currently considered to be low income by The World 
Bank, resources for health are expected to grow annually 
by 4·13% (3·75–4·55) between 2018 and 2030, although 
in per capita terms, annualised health spending growth 
is expected to be only 1·52% (1·15–1·93), reaching 
$45 (42–48) per capita in 2030.
Discussion
Disease-specific spending studies are valuable because 
they can provide policy makers and planners with 
insights into the financial burden created by specific 
diseases. This knowledge can subsequently be used in 
prioritisation, planning, budgeting, and evaluation of 
programmes; programme and policy interventions and 
development; and ultimately in better management of 
health systems. Our analysis quantified health sector 
spending and health spending on HIV/AIDS, tuber-
culosis, and malaria relative to outcomes, which are all 
priorities under SDG3. We also examined future 
availability of resources for health. Our results high-
light that, globally, total health spending has increased 
since the state of the SDGs in 2015, reaching $7·9 tril-
lion (7·8–8·0) in 2017, and is expected to increase to 
$11·0 trillion (10·7–11·2) by 2030, although with 
substan tial disparity across countries. In 2017, in low-
income and middle-income countries, an estimated 
$20·2 billion was spent on HIV/AIDS, $10·9 billion was 
spent on tuberculosis, and $5·1 billion was spent on 
malaria in endemic countries. Although both domestic 
government and DAH spending, has increased across 
these three diseases, the accom panied changes in 
outcomes have varied. We found that malaria had the 
most consistent decreases in outcomes across countries 
as spending has increased.
These health spending estimates enable further exami-
nation of the existing publicly available estimates of the 
financing required to achieve the SDG3 targets. Existing 
Figure 5: Out-of-pocket spending for health
(A) Out-of-pocket spending as a share of total health spending, in 2017. 
(B) Change in proportion of households with catastrophic health spending 
versus change in proportion of domestic health spending that is out-of-pocket, 
2000–17. Spending estimates are presented in 2019 US$. In panel A, estimates 
are plotted against GDP per capita with a loess regression line (span=0·95) and 
95% uncertainty intervals shaded in grey. Timor-Leste is excluded from panel B 
because the World Bank estimates for 2000–17 showed that no households in 
the country had catastrophic health spending. BLR=Belarus. GBD=Global Burden 
of Diseases, Injuries, and Risk Factors study. GDP=Gross Domestic Product. 
HTI=Haiti. IRL=Ireland. JOR=Jordan. LAO=Laos. MDV=Maldives. MNG=Mongolia. 
NER=Niger. RWA=Rwanda. SRB=Serbia. THA=Thailand. ZMB=Zambia.
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estimates suggest that the additional annual financing 
required to achieve SDG3 in 67 low-income and middle-
income countries is $274 billion (progress scenario in 
which the attainment of goals is limited by countries’ 
health systems existing absorptive capacity), and to 
reach health system targets for SDG3 including scale-up 
of health workforce and infrastructure is $371 billion.28 
Stenberg and colleagues estimated that to achieve SDG3 
in 67 low-income and middle-income countries, the 
corresponding per capita spending would need to 
increase to $249 per year (progress scenario) or $271 per 
year (ambitious scenario) by 2030.28 Another study by 
the Sustainable Development Solutions Network that 
included 59 low-income countries estimated that to 
achieve SDG3 would cost, approximately $225 billion 
between 2019 and 2030, with a per capita cost of $86 for 
low-income countries and $134 for lower-middle-income 
countries as the minimum needed to provide care 
consistent with basic human rights.39 A few other studies 
have also generated estimates of the resources needed 
using different methods.36,37,40 Our estimates suggest 
that 81 (60%) of 135 low-income and middle-income 
countries have not yet reached health spending of 
$249 per capita, and our projections suggest that 
75 countries might still not reach these goals by 2030.
Although these financing goals can be benchmarks to 
encourage more spending and increased health system 
efficiency, they do not ensure that SDG3 will be achieved. 
Ultimately, costing estimates like these need to be con-
tinuously improved to make them locally relevant and 
price appropriate, with realistic assumptions about 
health system inefficiency and the distribution of 
spending in a country, and to incorporate any challenges 
associated with preventing and treating disease in 
difficult to reach contexts.
For all three diseases for which a complete and compa-
rable series of spending estimates exist in low-income 
and middle-income countries—HIV/AIDS, tuber culosis, 
and malaria—comparing the relative con tributions from 
the different financing sources high lights interesting 
patterns. Governments contribute substantially across 
all three diseases. This observation is important because 
domestic resource mobilisation has received renewed 
interest as a key strategy for gener ating resources to 
finance the SDGs.4 While DAH contributions to malaria 
and HIV/AIDS are substantial, contributions to tuber-
culosis are smaller. This pattern brings into light long-
standing concerns and debate regarding the allocation 
of DAH especially across health focus areas.41–43 These 
concerns and debate include whether the current criteria 
that rely mainly on a country’s level of development 
are the most appro priate to use for allocation, donor 
preference for implementing vertical programmes with 
short-term measurable effects, and prioritisation of 
such diseases to broader health system challenges. Also, 
the relative dependence on household out-of-pocket 
spending across the three diseases is notable, with the 
proportion of out-of-pocket spending for tuberculosis 
and malaria being much larger than the proportion for 
HIV/AIDS. Changes in policy, such as making HIV 
treatment available and free to all, has transformed 
management of care for HIV/AIDS and its by-source 
Figure 6: Development assistance for health
(A) Changes in development assistance for health by health focus area, 1990–2019. (B) Annualised rate of change in development assistance for health by health 
focus area, 2000–15 and 2015–19. Estimates are presented in billions of 2019 US$. GBD=Global Burden of Diseases, Injuries, and Risk Factors study. *Data for 2018 
and 2019 are preliminary estimates based on budget data and estimation.
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funding distribution. Previous studies have shown that 
high out-of-pocket spending promotes health impover-
ishment.17,44,45 Hence, targeted efforts, such as public 
education campaigns on enrolment in national health 
insurance or free provision of services where appro-
priate, aimed at increasing the share of national health 
spending that is financed through pooled resources 
might improve financial protection.
The distribution of health spending by source across 
different regions also highlights heterogeneous health 
financing patterns for the three diseases globally. For 
some geographical regions (eg, Central Europe, eastern 
Europe, and central Asia, and sub-Saharan Africa), 
governments carry the primary burden of providing 
resources for these diseases, while in other regions (eg, 
southeast Asia, east Asia, and Oceania, and south Asia) 
the pattern of financing changes with the type of disease. 
Similarly, health spending globally has distinct patterns. 
In the high-income GBD super-region, spending by 
governments dominates, while in other super-regions, 
such as south Asia and sub-Saharan Africa, DAH and 
out-of-pocket spending are prominent. Preferably, 
resources for financing health care should be pooled 
to restrict the risk of health impoverishment for the 
population and delays in accessing needed care. 
Resources for financing health care could be pooled 
through government facilitation of the development of 
viable prepaid mandatory insurance programmes.
The association between spending on health and health 
outcomes is of interest to many audiences, especially 
because of the increases in spending on health that have 
been observed in the past two decades with the adoption 
of the MDGs and now the SDGs. Our results highlight 
a nuanced and complex picture regarding the link 
between health spending and its associated effect on 
outcomes—here, disease-specific outcomes. Although 
substantial reductions in the inci dence of some diseases 
were observed as spending increased in some countries, 
in others decreases in the inci dence of other disease were 
minimal or even increases in incidence were seen. For 
example, for malaria, we observed that in Myanmar and 
eSwatini, per-capita spending increased at an annu alised 
rate of more than 15% from 2000 to 2017, and the 
annualised incidence rate decreased by more than 10%, 
while for tuberculosis, in eSwatini, Lesotho, and 
Nicaragua, we observed a more than 12% annualised rate 
of growth in per-capita spending with varying annualised 
rates of change in incidence (0·89% decrease for 
eSwatini, 0·04% increase for Lesotho, 2·14% decrease 
for Nicaragua). Because these findings are not causal, 
interest in understanding this link between spending on 
health and health outcomes is strong and more efforts 
would be needed to understand the drivers of success.
Overall, these results highlight the continued impor-
tance of domestic resource mobilisation in securing the 
financing required for the SDGs and the health-related 
SDGs in particular. Although donor contributions will be 
necessary to meet spending targets in some low-income 
countries, governments were an important source of 
funding in the broader health system and among the 
three disease areas for which data were available. For 
most middle-income countries, the aspiration is that 
national economic growth will also bolster what resources 
are allocated to the health sector by the government. 
Further more, although DAH will continue to be needed 
in some low-income countries, a continued need for and 
value in DAH provision to cover so-called global public 
goods or common goods for health exists (such as 
pandemic preparedness or research and development for 
neglected tropical diseases).35,46–52 This continued need is 
because the multisectoral nature of the SDGs and the 
increasingly interconnected world we live in present 
shared global challenges that need to be addressed 
beyond the individual country support framework that 
DAH has typically addressed.
In addition to the need to generate more resources to 
finance the health-related SDGs, the need to efficiently 
use existing resources should be highlighted. The 
comparison of the annualised rates of change of pooled 
health spending per capita and universal health cov erage 
index highlighted some of the best performers at each 
level of development. For example, Myanmar and 
Georgia show annualised growth in per-capita-pooled 
spending of more than 13%, which was associated with 
2·14% annualised growth in universal health coverage 
index in Myanmar and 0·05% in Georgia. Peer-to-peer 
country learning might facilitate the transfer of best 
practices in both the delivery and administration of the 
health sector in countries that are not yet performing 
optimally with their available resources. The second 
annual Universal Health Coverage Financing Forum 
organised by the World Bank high lighted strategies 
such as strategic purchasing, improve ment in data 
management systems, and organisational management 
that can be adopted to promote better efficiency for 
health.53 However, while important health gains can 
probably be made by increasing efficiency and investing 
in allied sectors, our future health spending estimates 
indicate that spending is expected to remain low in many 
countries, which raises concerns about the viability of 
reaching crucial SDG3 goals in those countries. In such 
countries, additional efforts to mobilise revenue, such as 
tax reforms where appropriate, are needed to ensure 
that adequate resources are available to support the 
achievement of the SDG3 goals.
Furthermore, the nuanced evidence on the scale-up of 
spending and improvements in health outcomes suggest 
a complex association between spending and health 
outcomes. This complexity highlights that, although 
more resources are likely to be needed to achieve SDG3, 
other constraints such as inefficient resource allocation, 
weak governance systems, drug shortages, and inadequate 
health workforce and management systems for health 
information in the broader health system that constrain 
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improvements in health outcomes will need to be 
addressed to achieve the SDG3 targets.
Finally, this study has also shown the gaps in current 
resource tracking efforts as they relate to the health-related 
SDGs. Most comparative data are available for the three 
diseases we studied but little comparable data on financing 
for most of the remaining indicators are available. This 
pattern might reflect funding priorities spurred by the 
MDGs. Given the broader orientation of the goals under 
the SDGs, a need exists for increased understanding on 
the financing for the other SDG3 targets.
Future research areas might include efforts targeted 
at financing health-related SDGs, such as hepatitis B, 
neglected tropical diseases, and non-communicable 
diseases, including substance abuse, alcohol use, road 
injury, adolescent birth, hazardous chemicals, and air, 
water, and soil pollution. Additionally, studies that 
aim to determine the types of spending that promote 
improvements in outcomes are needed to guide resource 
investments.
This study has several limitations. First, the data we used 
reported using different research units for each SDG3 
indicator. HIV/AIDS, tuberculosis, and malaria spending 
estimates were available for a subset of total countries. 
As such, although the available data is meaningful and 
contributes to our knowledge of spending on the SDGs, a 
directly comparable analysis of global spending inclusive 
of all countries on these indicators is currently constrained 
by gaps in the available data. Also, multiple competing cost 
estimates exist, and so the existing financing targets that 
we found for comparison with our spending estimates 
often differed in geographical scope, methods, and cur-
rency. These comparisons require precise and context-
specific costing estimates that incorporate realistic levels of 
efficacy. Second, some of the input data on global health 
spending used to generate total health spending estimates 
had questionable annual growth trends or did not provide 
direct information about the sources of the data. We used 
modelling methods to enable incorporation of these data 
but we acknowledge that challenges exist in terms of 
the quality of the available global health spending data. 
Additionally, we provided UIs for the estimates to provide 
information on the quality and precision of the estimates 
generated. Third, while the use of keywords to isolate 
relevant health focus and pro gramme areas for our DAH 
analysis is the best existing strategy for a comprehensive 
effort, it relies heavily on the project description provided 
in the databases and in some instances might not 
accurately reflect what the funds actually contributed to. 
Fourth, presenting spending at disease level might not be 
the level of aggregation that is most relevant for ministries 
of health and disaggregating at facility level (primary, 
secondary, and tertiary) or at expenditure-item level (staff, 
commodities) might be more readily useful to them. 
We plan to provide estimates that include these levels of 
disaggregation in the near future. Notably, our analysis 
of spending and outcomes was not designed to detect 
causality, but was primarily a descriptive analysis of 
the associations between these two metrics. Therefore, 
our findings should not be interpreted as causal. Fifth, 
when forecasting health expenditures, we are unable to 
incorporate fundamentally new and different policies or 
innovations that are outside of the bounds of the observed 
data. Current estimates do not directly account for mass 
migration due to conflict and are only able to be incor-
porated on the basis of these events being reflected in the 
underlying covariates.
Furthermore, due to data availability, our analyses 
mainly covered four SDG priority areas. Spending on 
several SDG3 targets, including hepatitis B incidence, 
substance abuse, chemical and environmental pollution 
do not yet have a comparable set of spending estimates, 
which would prohibit analyses. Ideally, estimates on 
DAH and domestic spending on all the priority areas 
under SDG3 will provide a more comprehensive picture. 
Nonetheless, we believe that the data and estimates we 
have provided are an adequate first step in monitoring 
the spending for these key SDG3 areas.
Finally, while each set of spending estimates is consistent 
and comparable on its own, the input data vary enough 
between diseases that the spending estimates between 
diseases are not perfectly comparable. For example, the 
HIV/AIDS and malaria government spending estimates 
are modelled on the basis of tabulated data, generally 
reporting total spending or budgets, while government 
spending estimates for tuberculosis and for out-of-pocket 
malaria and tuberculosis spending were based on taking 
the product of unit cost and service coverage estimates. 
These distinct estimation strategies will drive some 
differences, with unit cost and service coverage estimates 
not compre hensively including inefficient spending that 
does not yield increases in service coverage.
As of publication of this Article, health systems 
throughout the world are stretched thin addressing the 
effects of coronavirus disease 2019 (COVID-19). Over the 
past 5 months it has become increasingly clear that, 
although not yet fully realised, both the health and 
economic losses caused by this novel coronavirus will be 
immense. Because these costs are not yet known in full 
and because the pandemic is ongoing, the effects of 
COVID-19 have not been considered in the financing 
projections reported in this Article. If these costs lead to 
reductions in health spending as nations focus inward on 
economic woes or if these costs can be a catalyst for 
investment in robust public health systems and in shared 
vision of global health security remains to be seen.
The link between spending and changes in outcomes 
remains complex, and realistic country-specific spending 
targets for most SDG3 indicators do not exist. Under-
standing how much is being spent and where crucial 
gaps exist are the first steps in providing evidence for a 
global dialogue about how much investment is needed 
for health, where it should come from, and where and 
on whom it should be spent. Using the resources 
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available more efficiently and addressing broader 
health system constraints to service delivery, such as 
inadequate health information manage ment systems, 
weak governance systems, short ages in health workforce 
and pharmaceuticals, are crucial if substantial progress 
is to be made towards achieving the health-related 
SDGs. A key tenet under lying the SDG era is that “no 
one is left behind”. To achieve this goal by 2030, current 
efforts must expand to include the tracking of spending 
in all of these areas, increasing resources, and spending 
those resources more efficiently.
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